George Perry

List of Publications by Year
in descending order

779 papers	70,903 citations	489 128 h-index	1080 232 g-index
1061 all docs	1061 docs citations	1061 times ranked	61259 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	11.0	3,158
2	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy, 2008, 4, 151-175.	11.0	2,086
3	Oxidative Damage Is the Earliest Event in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 759-767.	1.8	1,691
4	Iron accumulation in Alzheimer disease is a source of redox-generated freeâ€‰radicals. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9866-9868.	7.6	1,280
5	Mitochondrial Abnormalities in Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 3017-3023.	3.8	1,195
6	Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease. Journal of Neuroscience, 2009, 29, 9090-9103.	3.8	1,031
7	Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1240-1247.	3.8	1,020
8	4â€Hydroxynonenalâ€Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease. Journal of Neurochemistry, 1997, 68, 2092-2097.	4.0	914
9	Oxidative Stress and Neurotoxicity. Chemical Research in Toxicology, 2008, 21, 172-188.	3.5	727
10	RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimerâ€™s Disease. Journal of Neuroscience, 1999, 19, 1959-1964.	3.8	715
11	Oxidative stress in Alzheimerâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 139-144.	3.8	680
12	Mitochondria dysfunction in the pathogenesis of Alzheimerâ€™s disease: recent advances. Molecular Neurodegeneration, 2020, 15, 30.	11.8	648
13	The Amyloid-Î² Pathway in Alzheimerâ€™s Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	8.2	643
14	Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 2-10.	3.8	617
15	Chemistry and Biochemistry of Oxidative Stress in Neurodegenerative Disease. Current Medicinal Chemistry, 2001, 8, 721-738.	2.5	576
16	Parkinson's Disease Is Associated with Oxidative Damage to Cytoplasmic DNA and RNA in Substantia Nigra Neurons. American Journal of Pathology, 1999, 154, 1423-1429.	4.1	574
17	Metal Binding and Oxidation of Amyloid-Î² within Isolated Senile Plaque Cores:Â Raman Microscopic Evidenceâ€. Biochemistry, 2003, 42, 2768-2773.	2.6	552
18	Amyloidâ€Î² Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress. Journal of Neurochemistry, 1998, 70, 2212-2215.	4.0	509

#	Article	IF	Citations
19	Involvement of Oxidative Stress in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 631-641.	1.8	496
20	In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimerâ€™s Disease. Journal of Neurochemistry, 2000, 74, 270-279.	4.0	494
21	Radical AGEing in Alzheimer's disease. Trends in Neurosciences, 1995, 18, 172-176.	8.8	471
22	Microbes and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 979-984.	2.7	445
23	Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology, 2010, 59, 290-294.	4.2	443
24	Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimerâ€™s disease. Journal of Neurochemistry, 2012, 120, 419-429.	4.0	438
25	Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. Journal of Neurochemistry, 2001, 76, 435-441.	4.0	422
26	Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid Î²-peptide. Nature Medicine, 1995, 1, 693-699.	30.1	419
27	Alzheimer's disease: the two-hit hypothesis. Lancet Neurology, The, 2004, 3, 219-226.	10.4	403
28	Alzheimer Disease and Oxidative Stress. Journal of Biomedicine and Biotechnology, 2002, 2, 120-123.	2.3	391
29	Oxidative stress signalling in Alzheimer's disease. Brain Research, 2004, 1000, 32-39.	2.3	379
30	Evidence that the Î²-Amyloid Plaques of Alzheimer's Disease Represent the Redox-silencing and Entombment of AÎ² by Zinc. Journal of Biological Chemistry, 2000, 275, 19439-19442.	3.5	368
31	LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Human Molecular Genetics, 2012, 21, 1931-1944.	3.0	365
32	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-Î². Biochemistry, 2004, 43, 560-568.	2.6	364
33	Increased Iron and Free Radical Generation in Preclinical Alzheimer Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 19, 363-372.	2.7	362
34	Redox-active iron mediates amyloid-Î² toxicity. Free Radical Biology and Medicine, 2001, 30, 447-450.	4.5	361
35	Oxidative Stress Increases Expression and Activity of BACE in NT2 Neurons. Neurobiology of Disease, 2002, 10, 279-288.	4.5	357
36	Activation of p38 Kinase Links Tau Phosphorylation, Oxidative Stress, and Cell Cycle-Related Events in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2000, 59, 880-888.	1.8	332

#	Article	IF	Citations
37	Role of mitochondrial dysfunction in Alzheimer's disease. Journal of Neuroscience Research, 2002, 70, 357-360.	3.0	332
38	Neuronal Oxidative Stress Precedes Amyloid-Î² Deposition in Down Syndrome. Journal of Neuropathology and Experimental Neurology, 2000, 59, 1011-1017.	1.8	309
39	Microglial activation and amyloidâ€Î² clearance induced by exogenous heatâ€shock proteins. FASEB Journal, 2002, 16, 601-603.	0.5	303
40	Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Journal of Neurochemistry, 2003, 85, 1101-1108.	4.0	303
41	Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the â€˜two hitâ€™ hypothesis. Mechanisms of Ageing and Development, 2001, 123, 39-46.	4.6	300
42	Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of Ï„ Filament Formation. American Journal of Pathology, 2003, 162, 1623-1627.	4.1	298
43	Oxidative stress activates a positive feedback between the Î³â€•and Î²â€secretase cleavages of the Î²â€amyloid precursor protein. Journal of Neurochemistry, 2008, 104, 683-695.	4.0	296
44	Activation of NADPH Oxidase in Alzheimer's Disease Brains. Biochemical and Biophysical Research Communications, 2000, 273, 5-9.	2.2	280
45	Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. NeuroReport, 1999, 10, 2411-2415.	1.2	279
46	Amyloid-Î²: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-Î². Brain Research Reviews, 2003, 43, 1-16.	9.0	276
47	Role of metal dyshomeostasis in Alzheimer's disease. Metallomics, 2011, 3, 267.	2.5	276
48	Is oxidative damage the fundamental pathogenic mechanism of Alzheimerâ€™s and other neurodegenerative diseases?. Free Radical Biology and Medicine, 2002, 33, 1475-1479.	4.5	268
49	Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron. Journal of Biological Chemistry, 2005, 280, 20978-20986.	3.5	264
50	Systemic Increase of Oxidative Nucleic Acid Damage in Parkinson's Disease and Multiple System Atrophy. Neurobiology of Disease, 2002, 9, 244-248.	4.5	261
51	Alzheimer disease, the two-hit hypothesis: An update. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 494-502.	3.8	257
52	The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimerâ€™s disease. Journal of Neurochemistry, 2009, 109, 153-159.	4.0	251
53	How important is oxidative damage? Lessons from Alzheimerâ€™s disease. Free Radical Biology and Medicine, 2000, 28, 831-834.	4.5	249
54	Oxidative Stress in Diabetes and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 763-774.	2.7	249

#	Article	IF	Citations
55	Mitochondria: A therapeutic target in neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 212-220.	3.8	248
56	Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Research, 1998, 780, 260-269.	2.3	246
57	Neuroinflammation, Hyperphosphorylated Tau, Diffuse Amyloid Plaques, and Down-Regulation of the Cellular Prion Protein in Air Pollution Exposed Children and Young Adults. Journal of Alzheimer's Disease, 2012, 28, 93-107.	2.7	238
58	Cytochemical Demonstration of Oxidative Damage in Alzheimer Disease by Immunochemical Enhancement of the Carbonyl Reaction with 2,4-Dinitrophenylhydrazine. Journal of Histochemistry and Cytochemistry, 1998, 46, 731-735.	2.6	234
59	Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 135-142.	3.8	233
60	Tau phosphorylation in Alzheimer's disease: pathogen or protector?. Trends in Molecular Medicine, 2005, 11, 164-169.	7.1	225
61	Astrocytes Regulate Microglial Phagocytosis of Senile Plaque Cores of Alzheimer's Disease. Experimental Neurology, 1998, 149, 329-340.	4.1	224
62	The upâ€regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1Î±. Journal of Neurochemistry, 2009, 108, 1045-1056.	4.0	219
63	Carbonylâ€Related Posttranslational Modification of Neurofilament Protein in the Neurofibrillary Pathology of Alzheimer's Disease. Journal of Neurochemistry, 1995, 64, 2660-2666.	4.0	212
64	Redox metals and neu rodegenerative disease. Current Opinion in Chemical Biology, 1999, 3, 220-225.	6.4	211
65	Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics, 2019, 16, 666-674.	4.7	210
66	Identification of Ubiquilin, a Novel Presenilin Interactor That Increases Presenilin Protein Accumulation. Journal of Cell Biology, 2000, 151, 847-862.	5.2	206
67	Variably proteaseâ€sensitive prionopathy: A new sporadic disease of the prion protein. Annals of Neurology, 2010, 68, 162-172.	5.8	205
68	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.1	203
69	Induction of Heme Oxygenaseâ€1 mRNA and Protein in Neocortex and Cerebral Vessels in Alzheimer's Disease. Journal of Neurochemistry, 1995, 65, 1399-1402.	4.0	199
70	Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.	11.2	198
71	Active glycation in neurofibrillary pathology of Alzheimer disease: NÎµ-(Carboxymethyl) lysine and hexitol-lysine. Free Radical Biology and Medicine, 2001, 31, 175-180.	4.5	197
72	Amyloid-Î² and Ï„ serve antioxidant functions in the aging and Alzheimer brain. Free Radical Biology and Medicine, 2002, 33, 1194-1199.	4.5	194

#	Article	IF	Citations
73	Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiology of Aging, 2001, 22, 131-146.	3.2	191
74	In Alzheimer's Disease, Heme Oxygenase Is Coincident with Alz50, an Epitope of Ï„ Induced by 4â€Hydroxyâ€2â€Nonenal Modification. Journal of Neurochemistry, 2000, 75, 1234-1241.	4.0	191
75	Nucleic acid oxidation in Alzheimer disease. Free Radical Biology and Medicine, 2008, 44, 1493-1505.	4.5	189
76	Phosphorylation of Neurofilaments Is Altered in Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 1988, 47, 642-653.	1.8	186
77	Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Research, 1993, 623, 142-146.	2.3	186
78	Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease. Journal of Alzheimer's Disease, 1998, 1, 45-55.	2.7	185
79	From Aging to Alzheimer's Disease: Unveiling â€œThe Switchâ€•with the Senescence-Accelerated Mouse Model (SAMP8). Journal of Alzheimer's Disease, 2008, 15, 615-624.	2.7	181
80	Meta-analysis of Telomere Length in Alzheimerâ€™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1069-1073.	3.7	178
81	Lipoic Acid and N-acetyl Cysteine Decrease Mitochondrial-Related Oxidative Stress in Alzheimer Disease Patient Fibroblasts. Journal of Alzheimer's Disease, 2007, 12, 195-206.	2.7	177
82	Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neuroscience Letters, 2006, 406, 189-193.	2.1	176
83	Three Histidine Residues of Amyloid-Î² Peptide Control the Redox Activity of Copper and Iron. Biochemistry, 2007, 46, 12737-12743.	2.6	176
84	Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Research, 1998, 788, 232-236.	2.3	173
85	Overexpression of Heme Oxygenase in Neuronal Cells, the Possible Interaction with Tau. Journal of Biological Chemistry, 2000, 275, 5395-5399.	3.5	171
86	Pathomechanisms of TDPâ€43 in neurodegeneration. Journal of Neurochemistry, 2018, 146, 7-20.	4.0	171
87	Vascular Oxidative Stress: Impact and Therapeutic Approaches. Frontiers in Physiology, 2018, 9, 1668.	2.8	171
88	Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. Journal of Alzheimer's Disease, 2006, 9, 147-153.	2.7	170
89	Iron: The Redox-active Center of Oxidative Stress in Alzheimer Disease. Neurochemical Research, 2007, 32, 1640-1645.	3.3	170
90	Luteinizing hormone modulates cognition and amyloid-Î² deposition in Alzheimer APP transgenic mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 447-452.	3.8	169

#	Article	IF	Citations
91	Abnormal Mitochondrial Dynamics in the Pathogenesis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S253-S262.	2.7	168
92	Vascular oxidative stress in Alzheimer disease. Journal of the Neurological Sciences, 2007, 257, 240-246.	0.6	166
93	Chondroitin Sulfate Proteoglycans Are Associated with the Lesions of Alzheimer's Disease. Experimental Neurology, 1993, 121, 149-152.	4.1	165
94	Oxidative Damage to RNA in Aging and Neurodegenerative Disorders. Neurotoxicity Research, 2012, 22, 231-248.	2.7	165
95	Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neuroscience Letters, 2002, 319, 25-28.	2.1	164
96	Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. Journal of Neurochemistry, 2001, 76, 565-572.	4.0	163
97	Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe?. Acta Neuropathologica, 2003, 105, 524-528.	7.9	158
98	Luteinizing Hormone, a Reproductive Regulator That Modulates the Processing of Amyloid-Î² Precursor Protein and Amyloid-Î² Deposition. Journal of Biological Chemistry, 2004, 279, 20539-20545.	3.5	155
99	Tau â€“ an inhibitor of deacetylase HDAC6 function. Journal of Neurochemistry, 2009, 109, 1756-1766.	4.0	154
100	Alzheimer Disease Pathology As a Host Response. Journal of Neuropathology and Experimental Neurology, 2008, 67, 523-531.	1.8	153
101	The glucose transporter of the human brain and blood-brain barrier. Annals of Neurology, 1988, 24, 757-764.	5.8	150
102	4-Oxo-2-nonenal Is Both More Neurotoxic and More Protein Reactive than 4-Hydroxy-2-nonenal. Chemical Research in Toxicology, 2005, 18, 1219-1231.	3.5	149
103	Oxidative Stress Is an Early Event in Hydrostatic Pressureâ€“Induced Retinal Ganglion Cell Damage. , 2007, 48, 4580.		149
104	Abortive apoptosis in Alzheimer's disease. Acta Neuropathologica, 2001, 101, 305-310.	7.9	148
105	The Role of Oxidative Stress in the Pathophysiology of Cerebrovascular Lesions in Alzheimer's Disease. Brain Pathology, 2002, 12, 21-35.	4.2	147
106	Metabolic, Metallic, and Mitotic Sources of Oxidative Stress in Alzheimer Disease. Antioxidants and Redox Signaling, 2000, 2, 413-420.	5.5	146
107	Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 246-252.	3.8	146
108	Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. Journal of Neurochemistry, 2008, 79, 311-318.	4.0	146

#	Article	IF	Citations
109	Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neuroscience Letters, 2010, 468, 267-271.	2.1	145
110	Amyloid-Î² in Alzheimer Disease: The Null versus the Alternate Hypotheses. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 823-829.	2.4	144
111	Mitochondrial DNA Oxidative Damage and Repair in Aging and Alzheimer's Disease. Antioxidants and Redox Signaling, 2013, 18, 2444-2457.	5.5	144
112	Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathologica, 1995, 89, 291-295.	7.9	142
113	Prefrontal white matter pathology in air pollution exposed Mexico City young urbanites and their potential impact on neurovascular unit dysfunction and the development of Alzheimer's disease. Environmental Research, 2016, 146, 404-417.	7.7	142
114	PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer's disease. Human Molecular Genetics, 2016, 25, 792-806.	3.0	142
115	Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiology of Disease, 2004, 17, 108-113.	4.5	141
116	A Synergistic Dysfunction of Mitochondrial Fission/Fusion Dynamics and Mitophagy in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, S401-S412.	2.7	141
117	Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age, 2008, 30, 209-215.	2.9	140
118	Current approaches in the treatment of Alzheimer's disease. Biomedicine and Pharmacotherapy, 2008, 62, 199-207.	5.8	140
119	Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-Î² Protein Precursor and Amyloid-Î². Journal of Alzheimer's Disease, 2009, 18, 447-452.	2.7	140
120	Autophagocytosis of Mitochondria Is Prominent in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 525-532.	1.8	139
121	Nanoparticleâ€"chelator conjugates as inhibitors of amyloid-Î² aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease. Neuroscience Letters, 2009, 455, 187-190.	2.1	139
122	Paramyosin and actin in schistosomal teguments. Nature, 1988, 333, 76-78.	36.2	138
123	Three-Dimensional Tomographic Imaging and Characterization of Iron Compounds within Alzheimer's Plaque Core Material. Journal of Alzheimer's Disease, 2008, 14, 235-245.	2.7	138
124	Alzheimer Disease and the Role of Free Radicals in the Pathogenesis of the Disease. CNS and Neurological Disorders - Drug Targets, 2008, 7, 3-10.	1.6	137
125	Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease. Neurotoxicity Research, 2003, 5, 491-504.	2.7	135
126	RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathologica, 2009, 118, 151-166.	7.9	135

#	Article	IF	Citations
127	Î²-Amyloid of Alzheimer's Disease Induces Reactive Gliosis That Inhibits Axonal Outgrowth. Experimental Neurology, 1993, 124, 289-298.	4.1	133
128	Senile plaque composition and posttranslational modification of amyloid-Î² peptide and associated proteins. Peptides, 2002, 23, 1343-1350.	2.4	133
129	Hibernation, a Model of Neuroprotection. American Journal of Pathology, 2001, 158, 2145-2151.	4.1	132
130	Overview of Alzheimerâ€™s Disease and Some Therapeutic Approaches Targeting A<i>Î²</i>by Using Several Synthetic and Herbal Compounds. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-22.	4.1	131
131	Inhibition of mitochondrial fragmentation protects against Alzheimerâ€™s disease in rodent model. Human Molecular Genetics, 2017, 26, 4118-4131.	3.0	131
132	Antioxidant Therapy in Alzheimers Disease: Theory and Practice. Mini-Reviews in Medicinal Chemistry, 2008, 8, 1395-1406.	2.6	131
133	Hirano Body Filaments Contain Actin and Actin-Associated Proteins. Journal of Neuropathology and Experimental Neurology, 1987, 46, 185-199.	1.8	127
134	Oxidative Imbalance in Alzheimer's Disease. Molecular Neurobiology, 2005, 31, 205-218.	4.1	127
135	Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathologica, 2006, 111, 503-509.	7.9	127
136	Insulin is a Two-Edged Knife on the Brain. Journal of Alzheimer's Disease, 2009, 18, 483-507.	2.7	125
137	Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochemistry International, 2009, 54, 84-88.	3.9	125
138	AGEs/RAGE complex upregulates BACE1 via NF-Î°B pathway activation. Neurobiology of Aging, 2012, 33, 196.e13-196.e27.	3.2	125
139	Advances in Alzheimerâ€™s Diagnosis and Therapy: The Implications of Nanotechnology. Trends in Biotechnology, 2017, 35, 937-953.	9.5	125
140	Î±1-Antitrypsin and Î±1-antichymotrypsin are in the lesions of AlzheimerÊ¼s disease. NeuroReport, 1992, 3, 201-203.	1.2	123
141	Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. Journal of Neuroscience Research, 2002, 70, 514-518.	3.0	123
142	Clâˆ'-ATPase and Na+/K+-ATPase activities in Alzheimer's disease brains. Neuroscience Letters, 1998, 254, 141-144.	2.1	122
143	High Molecular Weight Neurofilament Proteins Are Physiological Substrates of Adduction by the Lipid Peroxidation Product Hydroxynonenal. Journal of Biological Chemistry, 2002, 277, 4644-4648.	3.5	122
144	Early Glycoxidation Damage in Brains from Down's Syndrome. Biochemical and Biophysical Research Communications, 1998, 243, 849-851.	2.2	121

#	Article	IF	Citations
145	Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. Journal of Neuroscience Research, 2003, 71, 863-870.	3.0	121
146	Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. Journal of Neurochemistry, 2014, 128, 162-172.	4.0	121
147	Oxidative Stress: The Old Enemy in Alzheimers Disease Pathophysiology. Current Alzheimer Research, 2005, 2, 403-408.	1.5	119
148	Increased Neuronal Glucose-6-phosphate Dehydrogenase and Sulfhydryl Levels Indicate Reductive Compensation to Oxidative Stress in Alzheimer Disease. Archives of Biochemistry and Biophysics, 1999, 370, 236-239.	3.2	117
149	Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radical Biology and Medicine, 2005, 38, 746-754.	4.5	117
150	Free radical damage, iron, and Alzheimer's disease. Journal of the Neurological Sciences, 1995, 134, 92-94.	0.6	116
151	The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders. CNS Drugs, 2002, 16, 339-352.	6.2	115
152	Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 731-740.	2.7	115
153	Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimerâ€™s disease. International Journal of Experimental Pathology, 2008, 89, 81-90.	1.3	114
154	DLP1â€dependent mitochondrial fragmentation mediates 1â€methylâ€4â€phenylpyridinium toxicity in neurons: implications for Parkinsonâ€™s disease. Aging Cell, 2011, 10, 807-823.	6.8	114
155	High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 24873.	3.4	114
156	Phosphorylation of Tau Protein as the Link between Oxidative Stress, Mitochondrial Dysfunction, and Connectivity Failure: Implications for Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-6.	4.1	113
157	Mitochondrial failures in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 2004, 19, 345-352.	2.0	112
158	MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents. Seminars in Cancer Biology, 2019, 56, 185-195.	9.8	111
159	Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 406-419.	1.5	111
160	Mechanisms of Neurotoxicity Associated with Amyloid Î² Deposition and the Role of Free Radicals in the Pathogenesis of Alzheimer's Disease:â€‰ A Critical Appraisal. Chemical Research in Toxicology, 1997, 10, 518-526.	3.5	110
161	Oxidative damage in Alzheimer's disease: the metabolic dimension. International Journal of Developmental Neuroscience, 2000, 18, 417-421.	1.6	108
162	A suicide note from Alzheimer disease neurons?. Nature Medicine, 1998, 4, 897-898.	30.1	107

#	Article	IF	Citations
163	Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Report, 2010, 15, 161-168.	4.6	107
164	All-<i>trans</i>retinoic acid as a novel therapeutic strategy for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2009, 9, 1615-1621.	2.8	106
165	Cellular prion protein is essential for oligomeric amyloid-Â-induced neuronal cell death. Human Molecular Genetics, 2012, 21, 1138-1144.	3.0	106
166	Increases in luteinizing hormone are associated with declines in cognitive performance. Molecular and Cellular Endocrinology, 2007, 269, 107-111.	3.3	105
167	Neuronal mitochondrial amelioration by feeding acetylâ€Lâ€carnitine and lipoic acid to aged rats. Journal of Cellular and Molecular Medicine, 2009, 13, 320-333.	3.6	105
168	The Earliest Stage of Cognitive Impairment in Transition From Normal Aging to Alzheimer Disease Is Marked by Prominent RNA Oxidation in Vulnerable Neurons. Journal of Neuropathology and Experimental Neurology, 2012, 71, 233-241.	1.8	105
169	Apoptosis and Alzheimer's Disease. , 1998, 282, 1265h-1265.		105
170	Antioxidant approaches for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 1201-1208.	2.8	104
171	Alzheimer disease: Evidence for a central pathogenic role of iron-mediated reactive oxygen species. Journal of Alzheimer's Disease, 2004, 6, 165-169.	2.7	102
172	Involvement of maillard reactions in Alzheimer disease. Neurotoxicity Research, 2002, 4, 191-209.	2.7	100
173	The cell cycle in Alzheimer disease: A unique target for neuropharmacology. Mechanisms of Ageing and Development, 2005, 126, 1019-1025.	4.6	100
174	Amyloid Beta: The Alternate Hypothesis. Current Alzheimer Research, 2006, 3, 75-80.	1.5	100
175	Oxidative Damage to RNA in Neurodegenerative Diseases. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-6.	2.3	100
176	NMR Studies of Zinc, Copper, and Iron Binding to Histidine, the Principal Metal Ion Complexing Site of Amyloid-Î² Peptide. Journal of Alzheimer's Disease, 2010, 20, 57-66.	2.7	100
177	Deconstructing Mitochondrial Dysfunction in Alzheimer Disease. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-13.	4.1	100
178	Slower Dynamics and Aged Mitochondria in Sporadic Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	4.1	99
179	Neuronal failure in Alzheimerâ€™s disease: a view through the oxidative stress looking-glass. Neuroscience Bulletin, 2014, 30, 243-252.	3.6	98
180	Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. Antioxidants and Redox Signaling, 2021, 34, 591-610.	5.5	98

#	Article	IF	Citations
181	Mechanisms by which metals promote events connected to neurodegenerative diseases. Brain Research Bulletin, 2001, 55, 125-132.	3.1	97
182	Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. BioMetals, 2003, 16, 77-81.	4.0	97
183	Hydroxynonenal, toxic carbonyls, and Alzheimer disease. Molecular Aspects of Medicine, 2003, 24, 305-313.	6.8	96
184	A novel approach to the identification and quantitative elemental analysis of amyloid depositsâ€"Insights into the pathology of Alzheimerâ€™s disease. Biochemical and Biophysical Research Communications, 2009, 382, 91-95.	2.2	96
185	Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Research Reviews, 2004, 3, 319-326.	11.2	95
186	Signal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 11, 143-152.	2.7	95
187	Insights into amyloid-Î²-induced mitochondrial dysfunction in Alzheimer disease. Free Radical Biology and Medicine, 2007, 43, 1569-1573.	4.5	95
188	Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurological Research, 2003, 25, 665-674.	1.4	94
189	Posttranslational modifications of Î±-tubulin in alzheimer disease. Translational Neurodegeneration, 2015, 4, 9.	8.2	94
190	Hirano bodies contain tau protein. Brain Research, 1987, 403, 337-340.	2.3	92
191	Carnosine: A Versatile Antioxidant and Antiglycating Agent. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe12-pe12.	0.3	92
192	Vascular abnormalities: the insidious pathogenesis of Alzheimerâ€™s diseaseâ˜†. Neurobiology of Aging, 2000, 21, 357-361.	3.2	91
193	Apoptosis in Alzheimer Disease: A Mathematical Improbability. Current Alzheimer Research, 2006, 3, 393-396.	1.5	91
194	Nanoparticle and Iron Chelators as a Potential Novel Alzheimer Therapy. Methods in Molecular Biology, 2010, 610, 123-144.	0.0	90
195	Nanoscale synchrotron X-ray speciation of iron and calcium compounds in amyloid plaque cores from Alzheimer's disease subjects. Nanoscale, 2018, 10, 11782-11796.	5.8	90
196	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Laboratory Investigation, 2019, 99, 958-970.	3.9	90
197	The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Annals of Neurology, 1989, 26, 771-778.	5.8	89
198	Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell, 2003, 2, 105-110.	6.8	89

#	Article	IF	Citations
199	Intraneuronal amyloid Î² accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiology of Disease, 2010, 37, 731-737.	4.5	89
200	Mitochondrial Dynamics in AlzheimerÊ¼s Disease. Drugs and Aging, 2010, 27, 181-192.	3.0	89
201	The state versus amyloid-Î²: the trial of the most wanted criminal in Alzheimer disease. Peptides, 2002, 23, 1333-1341.	2.4	88
202	Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell, 2004, 3, 41-44.	6.8	87
203	Role of high mobility group protein-1 (HMG1) in amyloid-Î² homeostasis. Biochemical and Biophysical Research Communications, 2003, 301, 699-703.	2.2	86
204	Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress. Archives of Medical Research, 2012, 43, 694-698.	3.5	86
205	Parallels Between Major Depressive Disorder and Alzheimerâ€™s Disease: Role of Oxidative Stress and Genetic Vulnerability. Cellular and Molecular Neurobiology, 2014, 34, 925-949.	3.3	86
206	Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the hippocampus and cortex. Molecular Neurodegeneration, 2018, 13, 5.	11.8	85
207	Omics sciences for systems biology in Alzheimerâ€™s disease: State-of-the-art of the evidence. Ageing Research Reviews, 2021, 69, 101346.	11.2	85
208	Soluble derivatives of the Î² amyloid protein precursor of Alzheimer's disease are labeled by antisera to the Î² amyloid protein. Biochemical and Biophysical Research Communications, 1989, 165, 182-188.	2.2	84
209	The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic Mouse. American Journal of Pathology, 2009, 174, 891-897.	4.1	84
210	Lipoperoxidation Is Selectively Involved in Progressive Supranuclear Palsy. Journal of Neuropathology and Experimental Neurology, 2000, 59, 393-397.	1.8	83
211	The neuroprotective activities of melatonin against the Alzheimer Î²-protein are not mediated by melatonin membrane receptors. Journal of Pineal Research, 2002, 32, 135-142.	7.7	83
212	Markers of oxidative damage to lipids, nucleic acids and proteins and antioxidant enzymes activities in Alzheimer's disease brain: A meta-analysis in human pathological specimens. Free Radical Biology and Medicine, 2018, 115, 351-360.	4.5	83
213	Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-Î² peptide. Free Radical Biology and Medicine, 2007, 43, 1552-1559.	4.5	82
214	Microglia are associated with the extracellular neurofibrillary tangles of alzheimer disease. Brain Research, 1991, 558, 312-314.	2.3	81
215	Physiological regulation of tau phosphorylation during hibernation. Journal of Neurochemistry, 2008, 105, 2098-2108.	4.0	81
216	Mexico City normal weight children exposed to high concentrations of ambient PM2.5 show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease. Environmental Research, 2015, 140, 579-592.	7.7	81

#	Article	IF	Citations
217	Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 928-940.	1.5	81
218	Oxidative Stress, Antioxidants, and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2000, 14, S62-S66.	1.3	80
219	Accelerated Î±-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Research, 2004, 1013, 51-59.	2.3	80
220	Phosphorylated Tau: Toxic, Protective, or None of the Above. Journal of Alzheimer's Disease, 2008, 14, 377-383.	2.7	80
221	Amyloid-Î² junkies. Lancet, The, 2000, 355, 757.	12.1	79
222	Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion, 2004, 4, 649-663.	3.6	79
223	Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS): Architecture. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 615-620.	4.6	79
224	Precision pharmacology for Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 331-365.	7.2	79
225	The Alzheimer Precision Medicine Initiative. Journal of Alzheimer's Disease, 2019, 68, 1-24.	2.7	79
226	Alzheimer's Disease: Cerebrovascular Dysfunction, Oxidative stress, and Advanced Clinical Therapies. Journal of Alzheimer's Disease, 2008, 15, 199-210.	2.7	78
227	The complexities of the pathologyâ€“pathogenesis relationship in Alzheimer disease. Biochemical Pharmacology, 2014, 88, 671-676.	4.6	78
228	Amyloidâ€Î²â€induced toxicity of primary neurons is dependent upon differentiationâ€associated increases in tau and cyclinâ€dependent kinase 5 expression. Journal of Neurochemistry, 2004, 88, 554-563.	4.0	77
229	Alz 50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy. Annals of Neurology, 1988, 24, 407-413.	5.8	76
230	Overexpression of GRK2 in alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotoxicity Research, 2006, 10, 43-56.	2.7	76
231	c-Jun phosphorylation in Alzheimer disease. Journal of Neuroscience Research, 2007, 85, 1668-1673.	3.0	76
232	Mitochondrial traffic jams in Alzheimer's disease - pinpointing the roadblocks. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1909-1917.	3.8	76
233	Reactive Oxygen Species and Their Impact in Neurodegenerative Diseases: Literature Landscape Analysis. Antioxidants and Redox Signaling, 2021, 34, 402-420.	5.5	76
234	Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges. Journal of Alzheimer's Disease, 2019, 67, 447-467.	2.7	75

#	Article	IF	Citations
235	Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies. NeuroReport, 2002, 13, 2035-2039.	1.2	74
236	Polyphenols in Alzheimerâ€™s Disease and in the Gutâ€“Brain Axis. Microorganisms, 2020, 8, 199.	3.6	74
237	Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy. Seminars in Cancer Biology, 2021, 69, 150-165.	9.8	74
238	Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease. Journal of Neurochemistry, 1989, 52, 1523-1528.	4.0	73
239	AMYLOID PRECURSOR PROTEIN IN SENILE PLAQUES OF ALZHEIMER DISEASE. Lancet, The, 1988, 332, 746.	12.1	72
240	Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin?. Free Radical Biology and Medicine, 1999, 26, 1508-1512.	4.5	72
241	Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to Î² sheet in tau protein linked to Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 945-953.	5.7	72
242	RNA and Oxidative Stress in Alzheimerâ€™s Disease: Focus on microRNAs. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-16.	4.1	71
243	Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Research, 1998, 791, 63-66.	2.3	70
244	Amyloid-Î², tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?. Neurochemistry International, 2002, 40, 527-531.	3.9	70
245	Cholesterol, oxidative stress, and Alzheimerâ€™s disease: expanding the horizons of pathogenesis1 1This article is part of a series of reviews on â€œCauses and Consequences of Oxidative Stress in Alzheimerâ€™s Disease.â€•The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 33, 173-181.	4.5	70
246	Early AGEing and Alzheimer's. Nature, 1995, 374, 316-316.	36.2	69
247	Ectopic expression of phospho-Smad2 in Alzheimer's disease: Uncoupling of the transforming growth factor-Î² pathway?. Journal of Neuroscience Research, 2006, 84, 1856-1861.	3.0	69
248	TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration. Molecular and Cellular Neurosciences, 2019, 100, 103396.	2.2	69
249	A Primate Model for Human Cerebral Malaria: Plasmodium coatneyi-Infected Rhesus Monkeys. American Journal of Tropical Medicine and Hygiene, 1992, 46, 391-397.	3.5	69
250	Oxidative Damage to Nucleic Acids in Human Prion Disease. Neurobiology of Disease, 2002, 9, 275-281.	4.5	68
251	Telomeres and telomerase in Alzheimer's disease: Epiphenomena or a new focus for therapeutic strategy?. Alzheimer's and Dementia, 2006, 2, 164-168.	0.7	68
252	Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathologica, 2003, 106, 552-556.	7.9	67

#	Article	IF	Citations
253	Oxidative Stress and Neuronal Adaptation in Alzheimer Disease: The Role of SAPK Pathways. Antioxidants and Redox Signaling, 2003, 5, 571-576.	5.5	67
254	Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Molecular Neurodegeneration, 2008, 3, 13.	11.8	67
255	Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radical Research, 2009, 43, 156-164.	3.3	66
256	Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia. Journal of Bioenergetics and Biomembranes, 2009, 41, 433-440.	2.3	65
257	The role of iron as a mediator of oxidative stress in Alzheimer disease. BioFactors, 2012, 38, 133-138.	5.5	65
258	Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. Journal of Neuroscience Research, 2004, 75, 698-703.	3.0	64
259	Antioxidant protection and neurodegenerative disease: The role of amyloid-Î² and tau. American Journal of Alzheimer's Disease and Other Dementias, 2006, 21, 126-130.	2.0	64
260	Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain. Current Alzheimer Research, 2007, 4, 67-72.	1.5	64
261	Quantitative solubilization and analysis of insoluble paired helical filaments from alzheimer disease. Brain Research, 1996, 717, 99-108.	2.3	63
262	Prion Protein Glycosylation Is Sensitive to Redox Change. Journal of Biological Chemistry, 1999, 274, 34846-34850.	3.5	63
263	Phosphorylation of Tau protein correlates with changes in hippocampal theta oscillations and reduces hippocampal excitability in Alzheimer's model. Journal of Biological Chemistry, 2018, 293, 8462-8472.	3.5	63
264	Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine, 2020, 57, 102834.	6.0	63
265	Oxidative posttranslational modifications in Alzheimer disease. Molecular and Chemical Neuropathology, 1996, 28, 41-48.	1.0	62
266	Induction of HO-1 and NOS in Doppel-Expressing Mice Devoid of PrP: Implications for Doppel Function. Molecular and Cellular Neurosciences, 2001, 17, 768-775.	2.2	62
267	Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimerâ€™s disease. Acta Neuropathologica, 2004, 107, 365-371.	7.9	62
268	Causes versus effects: the increasing complexities of Alzheimerâ€™s disease pathogenesis. Expert Review of Neurotherapeutics, 2010, 10, 683-691.	2.8	62
269	Diet and Oxidative Stress: A Novel Synthesis of Epidemiological Data on Alzheimer's Disease*. Journal of Alzheimer's Disease, 1999, 1, 203-206.	2.7	60
270	JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. Journal of Neurochemistry, 2003, 85, 87-93.	4.0	60

#	Article	IF	Citations
271	Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget, 2016, 7, 38999-39016.	2.1	60
272	Chronic traumatic encephalopathy neuropathology might not be inexorably progressive or unique to repetitive neurotrauma. Brain, 2019, 142, 3672-3693.	8.0	60
273	Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2002, 133, 507-513.	2.7	59
274	Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants. Mini-Reviews in Medicinal Chemistry, 2007, 7, 171-180.	2.6	59
275	BRCA1 May Modulate Neuronal Cell Cycle Re-Entry in Alzheimer Disease. International Journal of Medical Sciences, 2007, 4, 140-145.	2.6	59
276	Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Molecular Neurodegeneration, 2007, 2, 2.	11.8	58
277	Biomarkers in Alzheimer's Disease: Past, Present and Future. Biomarkers in Medicine, 2010, 4, 15-26.	1.4	58
278	The impairment of insulin signaling in Alzheimer's disease. IUBMB Life, 2012, 64, 951-957.	3.6	58
279	Mitochondrial Importance in Alzheimerâ€™s, Huntingtonâ€™s and Parkinsonâ€™s Diseases. Advances in Experimental Medicine and Biology, 2012, 724, 205-221.	0.0	58
280	Perspectives on the Amyloid-Î² Cascade Hypothesis. Journal of Alzheimer's Disease, 2004, 6, 137-145.	2.7	57
281	LRRK2 protein is a component of lewy bodies. Annals of Neurology, 2006, 60, 617-618.	5.8	57
282	Neuroprotective effect of cocoa flavonids on in vitro oxidative stress. European Journal of Nutrition, 2009, 48, 54-61.	4.0	57
283	Detection and Localization of Markers of Oxidative Stress by In Situ Methods: Application in the Study of Alzheimer Disease. Methods in Molecular Biology, 2010, 610, 419-434.	0.0	57
284	BARHL1 Is Downregulated in Alzheimerâ€™s Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways. Genes, 2017, 8, 245.	2.4	57
285	Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential. Current Alzheimer Research, 2014, 11, 165-174.	1.5	57
286	Neurofilamentopathy in Neurodegenerative Diseases. The Open Neurology Journal, 2011, 5, 58-62.	0.4	57
287	Distribution, levels, and activation of MEK1 in Alzheimer's disease. Journal of Neurochemistry, 2004, 86, 136-142.	4.0	56
288	Miro1 deficiency in amyotrophic lateral sclerosis. Frontiers in Aging Neuroscience, 2015, 7, 100.	3.5	56

#	Article	IF	Citations
289	The presence of tau distinguishes Lewy bodies of diffuse Lewy body disease from those of idiopathic Parkinson disease. Neuroscience Letters, 1989, 100, 6-10.	2.1	55
290	Role of the antioxidant ascorbate in hibernation and warming from hibernation. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2002, 133, 483-492.	2.7	55
291	Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Research Reviews, 2003, 43, 164-178.	9.0	55
292	Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimerâ€™s disease pathogenesis. Neurobiology of Aging, 2004, 25, 599-602.	3.2	55
293	Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. Journal of the Neurological Sciences, 2005, 229-230, 285-292.	0.6	55
294	Altered Glycosylation Pattern of Proteins in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1998, 57, 905-914.	1.8	54
295	Protein Disulfide Isomerase in Alzheimer Disease. Antioxidants and Redox Signaling, 2000, 2, 485-489.	5.5	54
296	Neuroprotective properties of Bcl-w in Alzheimer disease. Journal of Neurochemistry, 2004, 89, 1233-1240.	4.0	54
297	Amyloid-Î² in Alzheimer's disease: the horse or the cart? Pathogenic or protective?. International Journal of Experimental Pathology, 2005, 86, 133-138.	1.3	54
298	Aberrant localization of importin Î±1 in hippocampal neurons in Alzheimer disease. Brain Research, 2006, 1124, 1-4.	2.3	54
299	Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the pathogenesis of Alzheimer’s disease. Vascular Health and Risk Management, 2008, Volume 4, 721-730.	2.3	54
300	Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2048-2059.	3.8	54
301	Levuglandin E2â^'Protein Adducts in Human Plasma and Vasculature. Chemical Research in Toxicology, 1997, 10, 536-545.	3.5	53
302	Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathologica, 2005, 110, 232-238.	7.9	53
303	Signaling effect of amyloid-Î²42 on the processing of AÎ²PP. Experimental Neurology, 2010, 221, 18-25.	4.1	53
304	Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Translational Neurodegeneration, 2015, 4, 14.	8.2	53
305	Curcumin/Melatonin Hybrid 5-(4-Hydroxy-phenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1<i>H</i>-indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 Mouse Model. ACS Chemical Neuroscience, 2015, 6, 1393-1399.	3.7	53
306	Telomere length in Parkinson's disease: A meta-analysis. Experimental Gerontology, 2016, 75, 53-55.	2.9	53

#	Article	IF	Citations
307	Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers. Current Alzheimer Research, 2018, 15, 164-181.	1.5	53
308	Biogenic metallic elements in the human brain?. Science Advances, 2021, 7, .	10.9	53
309	Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down's syndrome: a comparison with Alzheimer's disease. Brain Research, 1990, 537, 102-108.	2.3	52
310	Predicting the failure of amyloid-Î² vaccine. Lancet, The, 2002, 359, 1864-1865.	12.1	52
311	Homocysteine and Alzheimer's disease: a modifiable risk?. Free Radical Biology and Medicine, 2004, 36, 1471-1475.	4.5	52
312	A metabolic basis for Alzheimer disease. Neurochemical Research, 2003, 28, 1549-1552.	3.3	51
313	Autophagy in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 1209-1218.	2.8	51
314	A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks. Journal of Alzheimer's Disease, 2015, 44, 549-560.	2.7	51
315	APP transgenesis: Approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiology of Aging, 1996, 17, 153-171.	3.2	50
316	Causes and consequences of oxidative stress in Alzheimerâ€™s disease 1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is part of a series of reviews on â€œCauses and Consequences of Oxidative Stress in Alzheimerâ€™s Disease.â€• The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 32, 1049.	4.5	50
317	Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. Journal of Pathology, 2004, 203, 603-608.	4.5	50
318	Indoles as essential mediators in the gut-brain axis. Their role in Alzheimer's disease. Neurobiology of Disease, 2021, 156, 105403.	4.5	50
319	Therapeutic Opportunities in Alzheimer Disease: One for all or all for One?. Current Medicinal Chemistry, 2005, 12, 1137-1147.	2.5	49
320	Chronological primacy of oxidative stress in Alzheimer disease. Neurobiology of Aging, 2005, 26, 579-580.	3.2	49
321	Mitochondria: The Missing Link Between Preconditioning and Neuroprotection. Journal of Alzheimer's Disease, 2010, 20, S475-S485.	2.7	49
322	The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features. Journal of Alzheimer's Disease, 2017, 61, 17-28.	2.7	49
323	Lithium as a Treatment for Alzheimerâ€™s Disease: The Systems Pharmacology Perspective. Journal of Alzheimer's Disease, 2019, 69, 615-629.	2.7	49
324	Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radical Biology and Medicine, 1998, 25, 898-902.	4.5	48

#	Article	IF	Citations
325	Antigenâ€"antibody dissociation in Alzheimer disease: a novel approach to diagnosis. Journal of Neurochemistry, 2008, 106, 1350-1356.	4.0	48
326	Amyloid-Î² peptide structure in aqueous solution varies with fragment size. Journal of Chemical Physics, 2011, 135, 205101.	3.1	48
327	The Autistic Phenotype Exhibits a Remarkably Localized Modification of Brain Protein by Products of Free Radical-Induced Lipid Oxidation. American Journal of Biochemistry and Biotechnology, 2008, 4, 61-72.	0.4	48
328	Rimmed vacuoles of inclusion body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers. Brain Research, 1993, 603, 343-347.	2.3	47
329	Redox active iron accumulation in aceruloplasminemia. Neuropathology, 2008, 28, 466-471.	1.3	47
330	Estrogen receptor-Î± is localized to neurofibrillary tangles in Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 20352.	3.4	47
331	Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants. Free Radical Biology and Medicine, 2003, 34, 1070-1077.	4.5	46
332	Nuclear and mitochondrial DNA oxidation in Alzheimer's disease. Free Radical Research, 2012, 46, 565-576.	3.3	46
333	Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimerâ€™s Disease Treatment: Rethinking the Current Strategy. International Journal of Alzheimer's Disease, 2012, 2012, 1-7.	2.5	46
334	A Multilevel View of the Development of Alzheimerâ€™s Disease. Neuroscience, 2021, 457, 283-293.	2.4	46
335	Oxidative damage and Alzheimer's disease: Are antioxidant therapies useful?. Drug News and Perspectives, 2005, 18, 5.	1.0	46
336	Influence of neuronal location on antigenic properties of neurofibrillary tangles. Annals of Neurology, 1988, 23, 604-610.	5.8	45
337	[10] In situ methods for detection and localization of markers of oxidative stress: Application in neurodegenerative disorders. Methods in Enzymology, 1999, 309, 133-152.	1.7	45
338	Amyloid-Î²: a (life) preserver for the brain. Neurobiology of Aging, 2002, 23, 1097-1099.	3.2	45
339	Insulin signaling, diabetes mellitus and risk of Alzheimer disease. Journal of Alzheimer's Disease, 2005, 7, 81-84.	2.7	45
340	Age-Related Loss of the DNA Repair Response Following Exposure to Oxidative Stress. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 427-434.	3.7	44
341	Molecular Pathogenesis of Alzheimerâ€™s Disease: Reductionist versus Expansionist Approaches. International Journal of Molecular Sciences, 2009, 10, 1386-1406.	4.2	44
342	A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules. Laboratory Investigation, 2011, 91, 1777-1786.	3.9	44

#	Article	IF	Citations
343	Proteolytic Cleavage of Polymeric Tau Protein by Caspase-3: Implications for Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1145-1161.	1.8	44
344	Consequences of RNA oxidation on protein synthesis rate and fidelity: implications for the pathophysiology of neuropsychiatric disorders. Biochemical Society Transactions, 2017, 45, 1053-1066.	3.4	44
345	Role of antioxidants and a nutrient rich diet in Alzheimer's disease. Open Biology, 2020, 10, 200084.	3.7	44
346	Î±-Calcium-Calmodulin-Dependent Kinase II is Associated with Paired Helical Filaments of AlzheimerÊ¼s Disease. Journal of Neuropathology and Experimental Neurology, 1996, 55, 954-963.	1.8	43
347	The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiology of Aging, 2002, 23, 855-859.	3.2	43
348	Functional Implications of Antiestrogen Induction of Quinone Reductase: Inhibition of Estrogen-Induced Deoxyribonucleic Acid Damage. Molecular Endocrinology, 2003, 17, 1344-1355.	3.4	43
349	P38 Activation Mediates Amyloid-Î² Cytotoxicity. Neurochemical Research, 2005, 30, 791-796.	3.3	43
350	Antimicrobial peptide Î²-defensin-1 expression is upregulated in Alzheimerâ€™s brain. Journal of Neuroinflammation, 2013, 10, 127.	7.4	43
351	Ontogeny of the erythroid/HepG2-type glucose transporter (GLUT-1) in the rat nervous system. Developmental Brain Research, 1993, 72, 41-49.	1.8	42
352	Melatonin acts as antioxidant and pro-oxidant in an organotypic slice culture model of Alzheimer's disease. NeuroReport, 2001, 12, 1277-1280.	1.2	42
353	Amyloid-?: A vascular sealant that protects against hemorrhage?. Journal of Neuroscience Research, 2002, 70, 356-356.	3.0	42
354	Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 251-254.	5.0	42
355	Malignant glioma progression and nitric oxide. Neurochemistry International, 2006, 49, 764-768.	3.9	42
356	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	2.8	42
357	Mitofusin 2 Regulates Axonal Transport of Calpastatin to Prevent Neuromuscular Synaptic Elimination in Skeletal Muscles. Cell Metabolism, 2018, 28, 400-414.e8.	15.8	42
358	A Novel Endogenous Indole Protects Rodent Mitochondria and Extends Rotifer Lifespan. PLoS ONE, 2010, 5, e10206.	2.5	42
359	Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. Brain Research, 1992, 579, 350-352.	2.3	41
360	LRRK2 in Parkinson's disease and dementia with Lewy bodies. Molecular Neurodegeneration, 2006, 1, 17.	11.8	41

#	Article	IF	Citations
361	Therapeutic options in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2006, 6, 897-910.	2.8	41
362	Imaging the Alzheimer Brain. Journal of Alzheimer's Disease, 2011, 26, 1-27.	2.7	41
363	Ca2+-stimulated production of H2O2 from naphthoquinone oxidation in Arbacia eggs. Experimental Cell Research, 1981, 134, 65-72.	2.6	40
364	Fertilization stimulates lipid peroxidation in the sea urchin egg. Developmental Biology, 1985, 107, 58-65.	2.1	40
365	Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells. Journal of Neurochemistry, 2004, 89, 1224-1232.	4.0	40
366	Compensatory responses induced by oxidative stress in Alzheimer disease. Biological Research, 2006, 39, 7-13.	3.6	40
367	The Contribution of Luteinizing Hormone to Alzheimer Disease Pathogenesis. Clinical Medicine and Research, 2007, 5, 177-183.	0.9	40
368	Structures and free energy landscapes of aqueous zinc(II)-bound amyloid-Î²(1â€“40) and zinc(II)-bound amyloid-Î²(1â€“42) with dynamics. Journal of Biological Inorganic Chemistry, 2012, 17, 927-938.	2.8	40
369	The Role of the Microbiotaâ€“Gutâ€“Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases. Microorganisms, 2020, 8, 784.	3.6	40
370	Retinoic acid isomers protect hippocampal neurons from amyloid-Î² induced neurodegeneration. Neurotoxicity Research, 2005, 7, 243-250.	2.7	39
371	Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radical Biology and Medicine, 2012, 52, 699-704.	4.5	39
372	The Structures of the E22Î” Mutant-Type Amyloid-Î² Alloforms and the Impact of E22Î” Mutation on the Structures of the Wild-Type Amyloid-Î² Alloforms. ACS Chemical Neuroscience, 2013, 4, 310-320.	3.7	39
373	Cytochalasin B blocks sperm incorporation but allows activation of the sea urchin egg. Experimental Cell Research, 1980, 126, 333-342.	2.6	38
374	Role of cytokeratin intermediate filaments in transhepatic transport and canalicular secretion. Hepatology, 1990, 11, 435-448.	8.1	38
375	Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1740, 472-480.	3.8	38
376	Toll-like receptors in Alzheimer's disease. Journal of Neuroimmunology, 2020, 348, 577362.	2.4	38
377	Characterization of a Ca2+-stimulated lipid peroxidizing system in the sea urchin egg. Developmental Biology, 1985, 107, 47-57.	2.1	37
378	What are the facts and artifacts of the pathogenensis and etiology of Alzheimer disease?. Journal of Chemical Neuroanatomy, 1998, 16, 35-41.	2.2	37

#	Article	IF	Citations
379	Do Neurons Have a Choice in Death?. American Journal of Pathology, 2001, 158, 1-2.	4.1	37
380	Steroidogenic Acute Regulatory Protein (StAR): Evidence of Gonadotropin-Induced Steroidogenesis in Alzheimer Disease. Molecular Neurodegeneration, 2006, 1, 14.	11.8	37
381	The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Research, 2009, 1249, 244-250.	2.3	37
382	Nucleic acid oxidative damage in Alzheimer's diseaseâ€"explained by the hepcidin-ferroportin neuronal iron overload hypothesis?. Journal of Trace Elements in Medicine and Biology, 2016, 38, 1-9.	3.2	37
383	Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimerâ€™s disease. Molecular Psychiatry, 2016, 21, 1263-1271.	8.2	37
384	Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency. Current Alzheimer Research, 2013, 10, 987-1004.	1.5	37
385	Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology. Journal of Alzheimer's Disease, 2016, 55, 749-762.	2.7	36
386	Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2017, 8, 1232-1241.	3.7	36
387	Metal Chelators Coupled with Nanoparticles as Potential Therapeutic Agents for Alzheimer's Disease. Journal of Nanoneuroscience, 2009, 1, 42-55.	0.5	36
388	Coexistence of cytokeratin, vimentin and neurofilament protein in human choroid plexus. Virchows Archiv A, Pathological Anatomy and Histopathology, 1987, 410, 173-177.	1.3	35
389	MAPKs are differentially modulated in arctic ground squirrels during hibernation. Journal of Neuroscience Research, 2005, 80, 862-868.	3.0	35
390	The role of novel chitin-like polysaccharides in Alzheimer disease. Neurotoxicity Research, 2007, 12, 269-274.	2.7	35
391	Sublethal RNA Oxidation as a Mechanism for Neurodegenerative Disease. International Journal of Molecular Sciences, 2008, 9, 789-806.	4.2	35
392	Getting the iron out: Phlebotomy for Alzheimerâ€™s disease?. Medical Hypotheses, 2009, 72, 504-509.	1.5	35
393	Nanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!. CNS and Neurological Disorders - Drug Targets, 2012, 11, 81-85.	1.6	35
394	Chronic Effects of Mild Neurotrauma. Journal of Neuropathology and Experimental Neurology, 2015, 74, 493-499.	1.8	35
395	Thermodynamics of Amyloid-Î² Fibril Elongation: Atomistic Details of the Transition State. ACS Chemical Neuroscience, 2018, 9, 783-789.	3.7	35
396	Heme Catabolism and Heme Oxygenase in Neurodegenerative Disease. Antioxidants and Redox Signaling, 2004, 6, 888-894.	5.5	34

#	Article	IF	Citations
397	Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Molecular Neurodegeneration, 2009, 4, 32.	11.8	34
398	Dementia Pugilistica Revisited. Journal of Alzheimer's Disease, 2017, 60, 1209-1221.	2.7	34
399	Anthocyanins: Multi-Target Agents for Prevention and Therapy of Chronic Diseases. Current Pharmaceutical Design, 2018, 23, 6321-6346.	1.9	34
400	Atherosclerotic Lesions Are Associated with Increased Immunoreactivity for Inducible Nitric Oxide Synthase and Endothelin-1 in Thoracic Aortic Intimal Cells of Hyperlipidemic Watanabe Rabbits. Experimental and Molecular Pathology, 2001, 71, 40-54.	2.3	33
401	Beyond Estrogen: Targeting Gonadotropin Hormones in the Treatment of Alzheimers Disease. CNS and Neurological Disorders, 2004, 3, 281-285.	3.6	33
402	Striation is the characteristic neuritic abnormality in Alzheimer disease. Brain Research, 1998, 813, 329-333.	2.3	32
403	Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers. Hippocampus, 2010, 20, 902-905.	2.2	32
404	The Cell Cycle Regulator Phosphorylated Retinoblastoma Protein Is Associated With Tau Pathology in Several Tauopathies. Journal of Neuropathology and Experimental Neurology, 2011, 70, 578-587.	1.8	32
405	Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 63, 157-165.	2.7	32
406	Status and future directions of clinical trials in Alzheimer's disease. International Review of Neurobiology, 2020, 154, 3-50.	1.8	32
407	Serial reconstruction of Î²-protein amyloid plaques: relationship to microvessels and size distribution. Brain Research, 1992, 592, 278-282.	2.3	31
408	Melatonin reduces interleukin secretion in amyloid-Î² stressed mouse brain slices. Chemico-Biological Interactions, 2001, 134, 101-107.	4.2	31
409	Gender Differences in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 95-99.	1.3	31
410	Dissociated amyloid-Î² antibody levels as a serum biomarker for the progression of Alzheimerâ€™s disease: A population-based study. Experimental Gerontology, 2010, 45, 47-52.	2.9	31
411	MMR Vaccination: A Potential Strategy to Reduce Severity and Mortality of COVID-19 Illness. American Journal of Medicine, 2021, 134, 153-155.	1.4	31
412	Immunoaffinity demonstration that paired helical filaments of Alzheimer disease share epitopes with neurofilaments, MAP2 and tau. Brain Research, 1989, 484, 150-156.	2.3	30
413	Erythrocyte, plasma, and serum antioxidant activities in untreated toxic multinodular goiter patients. Free Radical Biology and Medicine, 2001, 30, 665-670.	4.5	30
414	Mitogen- and stress-activated protein kinase 1: Convergence of the ERK and p38 pathways in Alzheimer's disease. Journal of Neuroscience Research, 2005, 79, 554-560.	3.0	30

#	Article	IF	Citations
415	Emerging evidence for the neuroprotective role of Î±-synuclein. Experimental Neurology, 2006, 200, 1-7.	4.1	30
416	Elevation of Î²-Amyloid 1-42 Autoantibodies in the Blood of Amnestic Patients With Mild Cognitive Impairment. Archives of Neurology, 2010, 67, 867-72.	4.5	30
417	The Mitochondrial Dynamics of Alzheimers Disease and Parkinsons Disease Offer Important Opportunities for Therapeutic Intervention. Current Pharmaceutical Design, 2011, 17, 3374-3380.	1.9	30
418	Early contribution of oxidative glycation in Alzheimer disease. Neuroscience Letters, 1996, 217, 210-211.	2.1	29
419	Will antioxidants fulfill their expectations for the treatment of Alzheimer disease?. Mechanisms of Ageing and Development, 2000, 116, 169-179.	4.6	29
420	Mitochondrial preconditioning: a potential neuroprotective strategy. Frontiers in Aging Neuroscience, 2010, 2, .	3.5	29
421	Antibodies to the neuronal cytoskeleton are elicited by Alzheimer paired helical filament fractions. Brain Research, 1987, 420, 233-242.	2.3	28
422	Hypoperfusion, Mitochondria Failure, Oxidative Stress, and Alzheimer Disease. Journal of Biomedicine and Biotechnology, 2003, 2003, 162-163.	2.3	28
423	Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease. Current Alzheimer Research, 2004, 1, 97-101.	1.5	28
424	Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?. Neurological Research, 2004, 26, 547-553.	1.4	28
425	Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. Molecular and Cellular Biochemistry, 2005, 278, 203-212.	3.1	28
426	Betaâ€•amyloid 1â€•42 monomers, but not oligomers, produce <scp>PHF</scp> â€•like conformation of Tau protein. Aging Cell, 2016, 15, 914-923.	6.8	28
427	New Insights into the Mechanisms of Mitochondrial Preconditioning-Triggered Neuroprotection. Current Pharmaceutical Design, 2011, 17, 3381-3389.	1.9	28
428	Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells. Neurobiology of Aging, 2006, 27, 1588-1594.	3.2	27
429	Frontiers in Alzheimerâ€™s disease therapeutics. Therapeutic Advances in Chronic Disease, 2011, 2, 9-23.	2.6	27
430	Apolipoprotein E4 Prevents Growth of Malaria at the Intraerythrocyte Stage: Implications For Diff erences in Racial Susceptibility to Alzheimerâ€™s Disease. Journal of Health Care for the Poor and Underserved, 2013, 24, 70-78.	0.8	27
431	Neuropsychiatric genetics in developing countries: Current challenges. World Journal of Psychiatry, 2014, 4, 69.	2.8	27
432	Alteration of Phospholipase Câ€•Î´ Protein Level and Specific Activity in Alzheimer's Disease. Journal of Neurochemistry, 1995, 64, 2629-2634.	4.0	26

#	Article	IF	Citations
433	Towards an Integrative Understanding of tRNA Aminoacylationâ€"Dietâ€"Hostâ€"Gut Microbiome Interactions in Neurodegeneration. Nutrients, 2018, 10, 410.	4.2	26
434	The Research Centers in Minority Institutions (RCMI) Translational Research Network: Building and Sustaining Capacity for Multi-Site Basic Biomedical, Clinical and Behavioral Research. Ethnicity and Disease, 2019, 29, 135-144.	2.2	26
435	The Transformative Possibilities of the Microbiota and Mycobiota for Health, Disease, Aging, and Technological Innovation. Biomedicines, 2019, 7, 24.	3.3	26
436	Association of plasma YKL-40 with brain amyloid-Î² levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	3.2	26
437	Amyloidosis, advanced glycation end products and Alzheimer disease. NeuroReport, 1995, 6, 1595.	1.2	25
438	The Estrogen Myth. Drugs in R and D, 2006, 7, 187-193.	2.2	25
439	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimer's Research and Therapy, 2019, 11, 15.	6.4	25
440	Tropomyosin distinguishes Lewy bodies of Parkinson disease from other neurofibrillary pathology. Brain Research, 1991, 541, 347-349.	2.3	24
441	Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?. Brain Pathology, 2003, 13, 630-638.	4.2	24
442	Antibodies to Potato Virus Y Bind the Amyloid Î² Peptide. Journal of Biological Chemistry, 2008, 283, 22550-22556.	3.5	24
443	A brief guide to the science and art of writing manuscripts in biomedicine. Journal of Translational Medicine, 2020, 18, 425.	4.5	24
444	Oxidative Stress Induces Senescence in Cultured RPE Cells. The Open Neurology Journal, 2016, 10, 83-87.	0.4	24
445	Cerebral Hemorrhage and Amyloid-<FONT FACE=. Science, 2003, 299, 1014a-1014.	20.9	23
446	Indices of Metabolic Dysfunction and Oxidative Stress. Neurochemical Research, 2007, 32, 717-722.	3.3	23
447	Modification of Amyloid-Î²1-42 Fibril Structure by Methionine-35 Oxidation. Journal of Alzheimer's Disease, 2013, 37, 9-18.	2.7	23
448	Amyloid Î² peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. Neurobiology of Aging, 2013, 34, 2071-2076.	3.2	23
449	Laser-Induced In-Source Decay Applied to the Determination of Amyloid-Beta in Alzheimerâ€™s Brains. ACS Chemical Neuroscience, 2016, 7, 261-268.	3.7	23
450	Mitochondrial Abnormalities and Oxidative Imbalance in Neurodegenerative Disease. Science of Aging Knowledge Environment: SAGE KE, 2002, 2002, 16pe-16.	0.3	23

#	Article	IF	Citations
451	Abnormal accumulation of phospholipase C-Î´ in filamentous inclusions of human neurodegenerative diseases. Neuroscience Letters, 1993, 162, 183-186.	2.1	22
452	Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet. The Anatomical Record, 2000, 260, 16-25.	1.6	22
453	Metals and oxidative homeostasis in Alzheimer's disease. Drug Development Research, 2002, 56, 293-299.	3.0	22
454	Call for Elan to publish Alzheimer's trial details. Nature, 2002, 416, 677-677.	36.2	22
455	What is aging? What is its role in Alzheimer's disease? What can we do about it?. Journal of Alzheimer's Disease, 2005, 7, 247-253.	2.7	22
456	Î²â€Amyloid 1â€42 induces physiological transcriptional regulation of BACE1. Journal of Neurochemistry, 2012, 122, 1023-1031.	4.0	22
457	A Low-Molecular-Weight Ferroxidase Is Increased in the CSF of sCJD Cases: CSF Ferroxidase and Transferrin as Diagnostic Biomarkers for sCJD. Antioxidants and Redox Signaling, 2013, 19, 1662-1675.	5.5	22
458	Differences in structure and function between human and murine tau. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2024-2030.	3.8	22
459	Is amyloid Î²-protein glycated in AlzheimerÊ¼s disease?. NeuroReport, 1997, 8, 907-909.	1.2	21
460	Possible involvement of Wiskottâ€"Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer's disease. Neuroscience Letters, 2003, 346, 149-152.	2.1	21
461	The Cell Cycle and Hormonal Fluxes in Alzheimer Disease: A Novel Therapeutic Target. Current Pharmaceutical Design, 2006, 12, 691-697.	1.9	21
462	Mathematical modeling of microtubule dynamics: Insights into physiology and disease. Progress in Neurobiology, 2010, 92, 478-483.	5.8	21
463	Making the Case for Accelerated Withdrawal of Aducanumab. Journal of Alzheimer's Disease, 2022, 87, 1003-1007.	2.7	21
464	Characterization of the association of phospholipase C-Î´ with Alzheimer neurofibrillary tangles. Brain Research, 1995, 669, 217-224.	2.3	20
465	Serum amyloid P is not present in amyloid Î² deposits of a transgenic animal modela. NeuroReport, 1999, 10, 3229-3232.	1.2	20
466	Amyloid-Î² Vaccination: Testing the Amyloid Hypothesis?. American Journal of Pathology, 2006, 169, 738-739.	4.1	20
467	Development of iron chelatorâ€"nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Progress in Brain Research, 2009, 180, 97-108.	3.9	20
468	Intrahippocampal Amyloid-β (1-40) Injections Injure Medial Septal Neurons in Rats. Current Alzheimer Research, 2011, 8, 832-840.	1.5	20

#	Article	IF	Citations
469	Fibrillar Amyloid-Î² Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3Ã—Tg-AD Transgenic Mouse. Journal of Alzheimer's Disease, 2016, 52, 243-269.	2.7	20
470	Current needs for human and medical genomics research infrastructure in low and middle income countries: TableÂ1. Journal of Medical Genetics, 2016, 53, 438-440.	3.6	20
471	Single-channel permeability and glycerol affinity of human aquaglyceroporin AQP3. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 768-775.	2.7	20
472	The Microbiotaâ€"Gutâ€"Brain Axisâ€"Heart Shunt Part II: Prosaic Foods and the Brainâ€"Heart Connection in Alzheimer Disease. Microorganisms, 2020, 8, 493.	3.6	20
473	Dementia with argyrophilic grains. Annals of Neurology, 1991, 30, 853-853.	5.8	19
474	Evidence for a Novel Heme-Binding Protein, HasAh, in Alzheimer Disease. Antioxidants and Redox Signaling, 2000, 2, 137-142.	5.5	19
475	Tipping the Apoptotic Balance in Alzheimer's Disease: The Abortosis Concept. Cell Biochemistry and Biophysics, 2003, 39, 249-256.	1.8	19
476	The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease. Mechanisms of Ageing and Development, 2006, 127, 501-506.	4.6	19
477	Evidence for the Role of Luteinizing Hormone in Alzheimer Disease. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2007, 7, 300-303.	1.3	19
478	Upregulation of Presenilin 1 in Brains of Sporadic, Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 771-775.	2.7	19
479	Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-Î² Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2018, 62, 467-476.	2.7	19
480	TDP-43 inhibitory peptide alleviates neurodegeneration and memory loss in an APP transgenic mouse model for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165580.	3.8	19
481	Genetic evidence for oxidative stress in AlzheimerÊ¼s disease. NeuroReport, 1999, 10, 1355-1357.	1.2	18
482	Estrogen Replacement and Risk of Alzheimer Disease. JAMA - Journal of the American Medical Association, 2003, 289, 1100.	7.0	18
483	Alzheimer's disease: an intracellular movement disorder?. Trends in Molecular Medicine, 2005, 11, 391-393.	7.1	18
484	Gonadotropins: A cohesive gender-based etiology of Alzheimer disease. Molecular and Cellular Endocrinology, 2007, 260-262, 271-275.	3.3	18
485	Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. Journal of Cellular and Molecular Medicine, 2009, 13, 853-865.	3.6	18
486	Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease. Neuroscience Letters, 2009, 460, 180-184.	2.1	18

#	Article	IF	Citations
487	Widespread distribution of reticulon-3 in various neurodegenerative diseases. Neuropathology, 2010, 30, 574-579.	1.3	18
488	Roles of Oxidative Stress in Synaptic Dysfunction and Neuronal Cell Death in Alzheimerâ€™s Disease. Antioxidants, 2023, 12, 1628.	5.2	18
489	Induction of NADPH cytochrome P450 reductase by the Alzheimer Î²-protein. Amyloid as a â€˜foreign bodyâ€™. Journal of Neurochemistry, 2001, 78, 121-128.	4.0	17
490	4â€Hydroxynonenal contributes to NGF withdrawalâ€induced neuronal apoptosis. Journal of Neurochemistry, 2003, 85, 999-1005.	4.0	17
491	Therapeutic potential of oxidant mechanisms in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2004, 4, 995-1004.	2.8	17
492	Current research in biotechnology: Exploring the biotech forefront. Current Research in Biotechnology, 2019, 1, 34-40.	3.8	17
493	Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2040-2047.	3.8	17
494	Alzheimerâ€™s Disease Patients in the Crosshairs of COVID-19. Journal of Alzheimer's Disease, 2020, 76, 1-1.	2.7	17
495	Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease. Current Alzheimer Research, 2016, 14, 40-46.	1.5	17
496	The â€œDown'sâ€•Side of Mitochondria. Developmental Cell, 2002, 2, 255-256.	7.0	16
497	Drug Therapy in Alzheimer's Disease. New England Journal of Medicine, 2004, 351, 1911-1913.	30.1	16
498	Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved. Current Medicinal Chemistry - Central Nervous System Agents, 2005, 5, 51-62.	0.5	16
499	Mitochondrial Drugs for Alzheimer Disease. Pharmaceuticals, 2009, 2, 287-298.	3.9	16
500	Glycogen Synthase Kinase 3: A Point of Integration in Alzheimer's Disease and a Therapeutic Target?. International Journal of Alzheimer's Disease, 2012, 2012, 1-4.	2.5	16
501	Gutâ€“microbiotaâ€“microgliaâ€“brain interactions in Alzheimerâ€™s disease: knowledge-based, multi-dimensional characterization. Alzheimer's Research and Therapy, 2021, 13, 177.	6.4	16
502	Optogenetics: implications for Alzheimerâ€™s disease research and therapy. Molecular Brain, 2022, 15, 20.	3.0	16
503	Neuropathologic Changes Provide Insights into Key Mechanisms of Alzheimer Disease and Related Dementia. American Journal of Pathology, 2022, 192, 1340-1346.	4.1	16
504	Demonstration of a novel neurofilament associated antigen with the neurofibrillary pathology of Alzheimer and related diseases. Brain Research, 1991, 558, 43-52.	2.3	15

#	Article	IF	Citations
505	Mitochondrial abnormalities: A primary basis for oxidative damage in Alzheimer's disease. Drug Development Research, 1999, 46, 26-33.	3.0	15
506	Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits. , 0, , 341-361.		15
507	Heme Deficiency in Alzheimerâ€™s Disease: A Possible Connection to Porphyria. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-5.	2.3	15
508	Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 553-569.	2.7	15
509	Alterations of low molecular weight acid phosphatase protein level in Alzheimer's disease. Brain Research, 1995, 699, 125-129.	2.3	14
510	Trypsin interaction with the senile plaques of Alzheimer disease is mediated by Î²-protein precursor. Molecular and Chemical Neuropathology, 1996, 27, 145-154.	1.0	14
511	Ferric Cycle Activity and Alzheimer Disease. Current Neurovascular Research, 2005, 2, 261-267.	1.1	14
512	Tau modifiers as therapeutic targets for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 211-215.	3.8	14
513	Concealment of epitope by reduction and alkylation in prion protein. Biochemical and Biophysical Research Communications, 2005, 326, 652-659.	2.2	14
514	Treating the Lesions, Not the Disease. American Journal of Pathology, 2007, 170, 1457-1459.	4.1	14
515	The Key Role of Oxidative Stress in Alzheimer's Disease. , 2007, , 267-281.		14
516	Divalent metal transporter, iron, and Parkinson's disease: A pathological relationship. Cell Research, 2010, 20, 397-399.	12.2	14
517	Cerebrovascular and mitochondrial abnormalities in Alzheimerâ€™s disease: a brief overview. Journal of Neural Transmission, 2016, 123, 107-111.	2.9	14
518	Neuropsychiatric Disturbances and Diabetes Mellitus: The Role of Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-2.	4.1	14
519	Biochemistry of Neurodegeneration. Science, 2001, 291, 595c-597.	20.9	14
520	Now is the Time to Improve Cognitive Screening and Assessment for Clinical and Research Advancement. Journal of Alzheimer's Disease, 2022, 87, 305-315.	2.7	14
521	Targeting Gonadotropins: An Alternative Option for Alzheimer Disease Treatment. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-8.	2.3	13
522	Increased Expression of p130 in Alzheimer Disease. Neurochemical Research, 2007, 32, 639-644.	3.3	13

#	Article	IF	Citations
523	The essential role of ERK in 4â€oxoâ€2â€nonenalâ€mediated cytotoxicity in SHâ€SY5Y human neuroblastoma cells. Journal of Neurochemistry, 2009, 108, 1434-1441.	4.0	13
524	Drug Discovery for Neurodegenerative Diseases: Challenges and Novel Biochemical Targets. Journal of Alzheimer's Disease, 2011, 24, 1-2.	2.7	13
525	CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinsonâ€™s disease. Journal of Neural Transmission, 2011, 118, 23-26.	2.9	13
526	Molecular Neuropathogenesis of Alzheimerâ€˜s Disease: An Interaction Model Stressing the Central Role of Oxidative Stress. Future Neurology, 2012, 7, 287-305.	0.5	13
527	Elongation affinity, activation barrier, and stability of Aî²42 oligomers/fibrils in physiological saline. Biochemical and Biophysical Research Communications, 2017, 487, 444-449.	2.2	13
528	Gibbs Free-Energy Gradient along the Path of Glucose Transport through Human Glucose Transporter 3. ACS Chemical Neuroscience, 2018, 9, 2815-2823.	3.7	13
529	No Evidence of Increased Chronic Traumatic Encephalopathy Pathology or Neurodegenerative Proteinopathy in Former Military Service Members: A Preliminary Study. Journal of Alzheimer's Disease, 2019, 67, 1277-1289.	2.7	13
530	Potential longâ€term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. Alzheimer's and Dementia, 2022, 18, 1248-1259.	0.7	13
531	Histochemical and Immunocytochemical Approaches to the Study of Oxidative Stress. Clinical Chemistry and Laboratory Medicine, 2000, 38, 93-7.	2.3	12
532	Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Redox Report, 2007, 12, 119-124.	4.6	12
533	Differential Network Analyses of Alzheimerâ€™s Disease Identify Early Events in Alzheimerâ€™s Disease Pathology. International Journal of Alzheimer's Disease, 2014, 2014, 1-18.	2.5	12
534	Insights into the structural patterns of the antileishmanial activity of bi- and tricyclic N-heterocycles. Organic and Biomolecular Chemistry, 2016, 14, 7053-7060.	2.9	12
535	Characterization of Proteins Present in Isolated Senile Plaques from Alzheimerâ€™s Diseased Brains by MALDI-TOF MS with MS/MS. ACS Chemical Neuroscience, 2018, 9, 708-714.	3.7	12
536	An Inducible Alpha-Synuclein Expressing Neuronal Cell Line Model for Parkinsonâ€™s Disease1. Journal of Alzheimer's Disease, 2018, 66, 453-460.	2.7	12
537	Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: A Morphological Study. Journal of Alzheimer's Disease, 2019, 71, 631-645.	2.7	12
538	The Interrelation of Neurological and Psychological Symptoms of COVID-19: Risks and Remedies. Journal of Clinical Medicine, 2020, 9, 2624.	2.5	12
539	Therapeutic Antiaging Strategies. Biomedicines, 2022, 10, 2515.	3.3	12
540	A Second Look into the Oxidant Mechanisms in Alzheimers Disease. Current Neurovascular Research, 2005, 2, 179-184.	1.1	11

#	Article	IF	Citations
541	Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Molecular BioSystems, 2011, 7, 1891.	2.8	11
542	Global warming and neurodegenerative disorders: speculations on their linkage. BioImpacts, 2014, 4, 167-170.	1.6	11
543	The sterol regulatory elementâ€binding protein 2 is dysregulated by tau alterations in Alzheimer disease. Brain Pathology, 2019, 29, 530-543.	4.2	11
544	Oxidative Stress Signaling in Blast TBI-Induced Tau Phosphorylation. Antioxidants, 2021, 10, 955.	5.2	11
545	Neuropathology in Alzheimer's Disease: Awaking from a Hundred-Year-Old Dream. Science of Aging Knowledge Environment: SAGE KE, 2006, 2006, pe10-pe10.	0.3	11
546	Alzheimer Disease Pathology in Middle Age Reveals a Spatial-Temporal Disconnect Between Amyloid-Î² and Phosphorylated Tau. The Open Neurology Journal, 2014, 8, 22-26.	0.4	11
547	RNA Oxidation in Alzheimer and Parkinson Diseases. Rejuvenation Research, 1999, 2, 227-230.	0.2	10
548	Menopause, Estrogen, and Gonadotropins in Alzheimer's Disease. Advances in Clinical Chemistry, 2008, 45, 139-153.	3.3	10
549	Entropy of corneal nerve fibers distribution observed by laser scanning confocal microscopy: A noninvasive quantitative method to characterize the corneal innervation in <scp>S</scp>jogren's syndrome patients. Microscopy Research and Technique, 2015, 78, 1069-1074.	2.3	10
550	Affinity and path of binding xylopyranose unto E.Âcoli xylose permease. Biochemical and Biophysical Research Communications, 2017, 494, 202-206.	2.2	10
551	Gait Disorders in Alzheimerâ€™s Disease and Other Dementias: There is Something in the Way You Walk. Journal of Alzheimer's Disease, 2019, 71, S1-S4.	2.7	10
552	Transplantation of Human Chorion-Derived Cholinergic Progenitor Cells: a Novel Treatment for Neurological Disorders. Molecular Neurobiology, 2019, 56, 307-318.	4.1	10
553	Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer's disease. Neuroscience Letters, 1989, 103, 259-262.	2.1	9
554	Illâ€fated amyloidâ€Î² vaccine. Journal of Neuroscience Research, 2002, 69, 285-285.	3.0	9
555	Stem cell niches as clinical targets: the future of anti-ischemic therapy?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 590-591.	1.9	9
556	Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets. Pharmaceuticals, 2009, 2, 250-286.	3.9	9
557	Editorial (A New Era for Medicinal Chemistry). Mini-Reviews in Medicinal Chemistry, 2012, 12, 1-1.	2.6	9
558	TMEM230 Accumulation in Granulovacuolar Degeneration Bodies and Dystrophic Neurites of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1027-1033.	2.7	9

#	Article	IF	Citations
559	Drug-Abuse Nanotechnology: Opportunities and Challenges. ACS Chemical Neuroscience, 2018, 9, 2288-2298.	3.7	9
560	Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. Journal of Alzheimer's Disease, 2019, 69, 1077-1087.	2.7	9
561	Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration. Journal of Alzheimer's Disease, 2021, 79, 1517-1531.	2.7	9
562	Challenges and Strategies of Successful Mentoring: The Perspective of LEADS Scholars and Mentors from Minority Serving Institutions. International Journal of Environmental Research and Public Health, 2021, 18, 6155.	2.7	9
563	Molecular Mapping Alzheimer's Disease: MALDI Imaging of Formalin-fixed, Paraffin-embedded Human Hippocampal Tissue. The Open Neurology Journal, 2016, 10, 88-98.	0.4	9
564	Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity. International Journal of Circumpolar Health, 2002, 61, 32-40.	1.2	9
565	Elastase is associated with the neurofibrillary pathology of Alzheimer disease: a putative link between proteolytic imbalance and oxidative stress. Restorative Neurology and Neuroscience, 1996, 9, 213-217.	0.8	8
566	A diet at amyloid beta?. Neurobiology of Aging, 2001, 22, 161-163.	3.2	8
567	Iron homeostasis is maintained in the brain, but not the liver, following mild hypoxia. Redox Report, 2007, 12, 257-266.	4.6	8
568	Heme-a, the heme prosthetic group of cytochrome c oxidase, is increased in Alzheimer's disease. Neuroscience Letters, 2009, 461, 302-305.	2.1	8
569	Expression of growth hormone gene in the baboon eye. Experimental Eye Research, 2018, 169, 157-169.	2.7	8
570	Oxidative Stress and Alzheimerâ€™s Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2016, , 189-198.	0.0	8
571	Hypoxic Preconditioning Averts Sporadic Alzheimer's Disease-Like Phenotype in Rats: A Focus on Mitochondria. Antioxidants and Redox Signaling, 2022, 37, 739-757.	5.5	8
572	Altered redox balance in disease: Can we change the new equilibria?. Annals of Neurology, 2009, 65, 121-123.	5.8	7
573	Paraffin-embedded tissue (PET) blot method: Application to Alzheimer disease. Journal of Neuroscience Methods, 2010, 190, 244-247.	2.6	7
574	Mark Anthony Smith (1965â€"2010): Visionary, Alzheimer Researcher, and Editor-in-Chief of the Journal of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 1-2.	2.7	7
575	Journal of Parkinson's Disease â€" Birth of JAD's New Sister. Journal of Alzheimer's Disease, 2011, 25, 1-1.	2.7	7
576	Alternative neural circuitry that might be impaired in the development of Alzheimer disease. Frontiers in Neuroscience, 2015, 9, 145.	2.9	7

#	Article	IF	Citations
577	Chlamydia pneumoniae promotes dysfunction of pancreatic beta cells. Cellular Immunology, 2015, 295, 83-91.	3.0	7
578	From Neurodegeneration to Brain Health: AnÂIntegrated Approach. Journal of Alzheimer's Disease, 2015, 46, 271-283.	2.7	7
579	1,3-propanediol binds deep inside the channel to inhibit water permeation through aquaporins. Protein Science, 2016, 25, 433-441.	7.8	7
580	MSDC-0160 and MSDC-0602 Binding with Human Mitochondrial Pyruvate Carrier (MPC) 1 and 2 Heterodimer. International Journal of Knowledge Discovery in Bioinformatics, 2017, 7, 43-67.	0.8	7
581	Community Engagement Practices at Research Centers in U.S. Minority Institutions: Priority Populations and Innovative Approaches to Advancing Health Disparities Research. International Journal of Environmental Research and Public Health, 2021, 18, 6675.	2.7	7
582	Alterations of the X Chromosome in Lymphocytes of Alzheimerâ€™s Disease Patients. Current Alzheimer Research, 2015, 12, 990-996.	1.5	7
583	The Role of the Iron Stain in Assessing Intracranial Hemorrhage. The Open Neurology Journal, 2016, 10, 136-142.	0.4	7
584	Universal Isolation of Cross-Linked Peptides:â€‰ Application to Neurofibrillary Tangles. Bioconjugate Chemistry, 1999, 10, 112-118.	3.8	6
585	Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease. Letters in Drug Design and Discovery, 2005, 2, 479-482.	0.7	6
586	Presenilin mutation: A deadly first hit in Alzheimer disease. Free Radical Biology and Medicine, 2006, 40, 737-739.	4.5	6
587	Amyloid-Î², BACE, and oxidative stress in Alzheimer's disease, a commentary on â€œThe different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expressionâ€. Free Radical Biology and Medicine, 2006, 41, 188-189.	4.5	6
588	Untangling the Vascular Web from Alzheimer Disease and Oxidative Stress. Canadian Journal of Neurological Sciences, 2012, 39, 4-4.	0.6	6
589	Foreword (The Largest Unmet Market: Chronic Diseases of Aging). Mini-Reviews in Medicinal Chemistry, 2013, 13, 1-1.	2.6	6
590	Precision medicine using individualized biosimulations of drug dosing: Alzheimer's disease. , 2014, , .		6
591	Modulation of Parkinsonâ€™s Disease Associated Protein Rescues Alzheimerâ€™s Disease Degeneration. Journal of Alzheimer's Disease, 2016, 55, 73-75.	2.7	6
592	From Oxidative Stress to Ageing via Lifestyle, Nutraceuticals, Polypharmacy, and Neuropsychological Factors. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-2.	4.1	6
593	Ethanol-Fixed, Paraffin-Embedded Tissue Imaging: Implications for Alzheimerâ€™s Disease Research. Journal of the American Society for Mass Spectrometry, 2020, 31, 2416-2420.	3.1	6
594	Î±-Synuclein and tau, two targets for dementia. Studies in Natural Products Chemistry, 2020, 67, 1-25.	0.0	6

#	Article	IF	Citations
595	Immune modulations and immunotherapies for Alzheimerâ€™s disease: a comprehensive review. Reviews in the Neurosciences, 2022, 33, 365-381.	3.2	6
596	Fractal Analysis of Epithelial-Connective Tissue Interface in Basal Cell Carcinoma of the Skin. Current Bioinformatics, 2013, 8, 357-361.	1.3	6
597	Oxidative Stress in Parkinson`s Disease. The Open Pathology Journal, 2009, 3, 38-42.	0.9	6
598	Mitochondrial Fusion Suppresses Tau Pathology-Induced Neurodegeneration and Cognitive Decline. Journal of Alzheimer's Disease, 2021, 84, 1057-1069.	2.7	6
599	Implication of ferroptosis ironâ€dependent programmed cell death mechanism in neurodegeneration. Alzheimer's and Dementia, 2020, 16, e043978.	0.7	6
600	Protocol for quantitative analysis of paired helical filament solubilization: a method applicable to insoluble amyloids and inclusion bodies. Brain Research Protocols, 1997, 1, 247-252.	1.6	5
601	Apoptotic and Oxidative Indicators in Alzheimer's Disease. Neuromethods, 2002, , 225-246.	0.0	5
602	Oxidative Stress and Neurodegeneration: An Inevitable Consequence of Aging? Implications for Therapy. , 2010, , 305-323.		5
603	Alzheimer's Disease and Vascular Deficiency: Lessons from Imaging Studies and Down Syndrome. Current Gerontology and Geriatrics Research, 2012, 2012, 1-5.	1.8	5
604	Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 108-116.	1.5	5
605	Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data. Journal of Alzheimer's Disease, 2018, 63, 1269-1277.	2.7	5
606	Transgenic Mouse Models of Alzheimer's Disease. Frontiers in Neuroscience, 2008, , 1-18.	0.0	5
607	Functional and Genomic Features of Human Genes Mutated in Neuropsychiatric Disorders. The Open Neurology Journal, 2016, 10, 143-148.	0.4	5
608	Low Dose Pioglitazone Attenuates Oxidative Damage in Early Alzheimer's Disease by Binding mitoNEET. International Journal of Knowledge Discovery in Bioinformatics, 2015, 5, 24-45.	0.8	5
609	Methemoglobinemiaâ€"A biomarker and a link to ferric iron accumulation in Alzheimerâ€™s disease. Advances in Bioscience and Biotechnology (Print), 2014, 05, 12-18.	0.7	5
610	Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimerâ€™s Disease. Current Alzheimer Research, 2013, 10, 108-116.	1.5	5
611	Hyperphosphorylated Tau Relates to Improved Cognitive Performance and Reduced Hippocampal Excitability in the Young rTg4510 Mouse Model of Tauopathy. Journal of Alzheimer's Disease, 2022, 87, 529-543.	2.7	5
612	Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2023, 24, 12486.	4.2	5

#	Article	IF	Citations
613	Dangers of the amyloid-Î² vaccination. Acta Neuropathologica, 2002, 104, 110-110.	7.9	4
614	Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway. Redox Report, 2003, 8, 129-133.	4.6	4
615	Amyloids, Aggregates and Neuronal Inclusions: Good or Bad News for Neurons?. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2003, 3, 293-298.	0.2	4
616	Nuclear microscopy of diffuse plaques in the brains of transgenic mice. Nuclear Instruments & Methods in Physics Research B, 2005, 231, 326-332.	1.4	4
617	Solving the insoluble. Journal of Alzheimer's Disease, 2006, 9, 301-304.	2.7	4
618	Therapeutic potential of oxidative stress reduction in Alzheimer's disease. Future Neurology, 2006, 1, 1-4.	0.5	4
619	Natural Oxidant Balance in Parkinson Disease. Archives of Neurology, 2009, 66, 1445.	4.5	4
620	Plaques and tangles: Birthmarks of the aging soul. Biochemical Pharmacology, 2014, 88, 423-425.	4.6	4
621	Loss of JAM-C leads to impaired esophageal innervations and megaesophagus in mice. Ecological Management and Restoration, 2016, 29, 864-871.	0.5	4
622	Incubation with Cu(II) and Zn(II) salts enhances MALDIâ€TOF mass spectra of amyloidâ€beta and Î±â€synuclein toward in vivo analysis. Journal of Mass Spectrometry, 2018, 53, 162-171.	1.8	4
623	Rapid method towards proteomic analysis of dried blood spots by MALDI mass spectrometry. Clinical Mass Spectrometry, 2019, 12, 30-36.	1.9	4
624	National Dementia BioBank: A Strategy for the Diagnosis and Study of Neurodegenerative Diseases in MÃ©xico. Journal of Alzheimer's Disease, 2020, 76, 853-862.	2.7	4
625	SWADESH: A Comprehensive Platform for Multimodal Data and Analytics for Advanced Research in Alzheimerâ€™s Disease and Other Brain Disorders. Journal of Alzheimer's Disease, 2021, , 1-5.	2.7	4
626	FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimerâ€™s Disease: Benefits and Pitfalls. Diagnostics, 2023, 13, 2254.	2.8	4
627	Alzheimerâ€™s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?. International Journal of Molecular Sciences, 2024, 25, 3892.	4.2	4
628	Hibernation, a Model of Neuroprotection. Scientific World Journal, The, 2001, 1, 108-108.	2.2	3
629	Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Journal of Neurochemistry, 2003, 86, 1312-1312.	4.0	3
630	Commentary: â€œCeramide and cholesterol: Possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?â€•By Claudio Costantini, Rekha M.K. Kolasani, and Luigi Puglielli. Alzheimer's and Dementia, 2005, 1, 51-52.	0.7	3

#	Article	IF	Citations
631	Neurofibrillary Tangle Formation as a Protective Response to Oxidative Stress in Alzheimerâ€™s Disease. , 2009, , 103-113.		3
632	Prospects on the Origin of Alzheimer's disease. Journal of Alzheimer's Disease, 2010, 20, 669-672.	2.7	3
633	Potential Role of Iron in a Mediterranean-style Diet. Archives of Neurology, 2010, 67, 1286.	4.5	3
634	In Vivo and In Silico Evidence: Hippocampal Cholesterol Metabolism Decreases with Aging and Increases with Alzheimers Disease -- Modeling Brain Aging and Disease. , 2011, , .		3
635	The origin of oxidative stress in neurodegenerative disease: Mark Anthony Smith 1965â€"2010. Free Radical Biology and Medicine, 2011, 51, 248-249.	4.5	3
636	Ethics Review as a Catalyst for Progress. Journal of Alzheimer's Disease, 2014, 40, 233-235.	2.7	3
637	Geometric complexity identifies platelet activation in familial hypercholesterolemic patients. Microscopy Research and Technique, 2015, 78, 519-522.	2.3	3
638	Antioxidants in theÂPrevention and Treatment of Alzheimerâ€™s Disease. , 2017, , 523-553.		3
639	IronÂ·ic facts about dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 446-447.	6.0	3
640	Genetic Risk of Alzheimerâ€™s Disease: Three Wishes Now That the Genie is Out of the Bottle. Journal of Alzheimer's Disease, 2018, 66, 421-423.	2.7	3
641	Neuropathology in Consecutive Forensic Consultation Cases with a History of Remote Traumatic Brain Injury. Journal of Alzheimer's Disease, 2019, 72, 683-691.	2.7	3
642	Interaction of Calcium-Calmodulin in Microtubule Assembly in Vitro. , 1982, , 73-84.		3
643	Editorial - Chronic or Late Lyme Neuroborreliosis: Present and Future. The Open Neurology Journal, 2012, 6, 78-78.	0.4	3
644	Transcriptome-To-Metabolomeâ„¢ Biosimulation Reveals Human Hippocampal Hypometabolism with Age and Alzheimerâ€™s Disease. International Journal of Knowledge Discovery in Bioinformatics, 2011, 2, 1-18.	0.8	3
645	Mechanisms Involved in Gender Differences in Alzheimer's Disease: The Role of Leuteinizing and Follicle Stimulating Hormones. , 2004, , 1234-1237.		3
646	Microtubules are not altered in the dystrophic chicken. Experimental Cell Research, 1986, 163, 266-272.	2.6	2
647	Oxidative Damage and Antioxidant Responses in Alzheimer's Disease. , 0, , 371-378.		2
648	Oxidative Stress Mechanisms and Potential Therapeutic Modalities in Alzheimer Disease. Medicinal Chemistry Reviews Online, 2004, 1, 19-23.	0.1	2

#	Article	IF	Citations
649	In Situ Localization of Nonenzymatic Peroxidaseâ€Like Activity of Tissueâ€Bound Transition Metals. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2004, 20, Unit17.4.	1.3	2
650	Prospects for Antioxidant Therapy in Mild Cognitive Impairment and Alzheimer's Disease. , 2007, , 451-466.		2
651	Cerebrotendinous xanthomatosis: a critical update. Future Neurology, 2008, 3, 491-501.	0.5	2
652	Mitochondria and Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2010, 20, S253-S253.	2.7	2
653	Iron Chelation and Nanoparticle Target Delivery in the Development of New Multifunctional disease-modifying Drugs for Alzheimerâ€˜s Disease. Therapeutic Delivery, 2012, 3, 571-574.	2.5	2
654	Alzheimer's Disease: Advances for a New Century. Journal of Alzheimer's Disease, 2012, 33, S1-S1.	2.7	2
655	Geometric complexity is increased in in vitro activated platelets. Microscopy Research and Technique, 2015, 78, 485-488.	2.3	2
656	Promise from the Sea. Marine Drugs, 2016, 14, 178.	4.6	2
657	Alzheimer's and Parkinson's Disease Novel Therapeutic Target. International Journal of Knowledge Discovery in Bioinformatics, 2017, 7, 68-82.	0.8	2
658	Clinical biomarkers for cancer recognition and prevention: A novel approach with optical measurements. Cancer Biomarkers, 2018, 22, 179-198.	1.7	2
659	Editorial: Oxidative Stress Revisitedâ€"Major Role in Vascular Diseases. Frontiers in Physiology, 2019, 10, 788.	2.8	2
660	Strawberry (Fragaria ananassa duch.) Alba extract attenuates DNA damage in lymphocytes of patients with Alzheimerâ€™s disease. Journal of Food Biochemistry, 2021, 45, e13637.	2.9	2
661	Conformation- and phosphorylation-dependent electron tunnelling across self-assembled monolayers of tau peptides. Journal of Colloid and Interface Science, 2022, 606, 2038-2050.	9.6	2
662	Alzheimerâ€™s Disease Pharmacology. , 2022, , 34-63.		2
663	The Role of Oxidative Stress in the Pathological Sequelae of Alzheimer Disease. , 1998, , 195-204.		2
664	Oxidative Stress in Alzheimerâ€™s Disease: A Critical Appraisal of the Causes and the Consequences. , 2011, , 211-220.		2
665	Hippocampal Unicellular Recordings and Hippocampal-dependent Innate Behaviors in an Adolescent Mouse Model of Alzheimerâ€™s disease. Bio-protocol, 2020, 10, e3529.	0.4	2
666	The Pathology of Alzheimer Disease Elicits an In Vivo Immunological Response. American Journal of Immunology, 2007, 3, 10-14.	0.1	2

#	Article	IF	Citations
667	The Role of Oxidative Damage to Nucleic Acids in the Pathogenesis of Neurological Disease. , 2007, , 123-140.		2
668	Two Hits and Youâ€™re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease. , 2008, , 191-204.		2
669	Natural Product Co-Metabolism and the Microbiotaâ€“Gutâ€“Brain Axis in Age-Related Diseases. Life, 2023, 13, 41.	2.5	2
670	A STUDY OF ACTIN BINDING PROTEINS IN HIRANO BODIES. Journal of Neuropathology and Experimental Neurology, 1986, 45, 335.	1.8	1
671	Arachidonic acid metabolism in Ascidia ceratodes eggs: role of lipid peroxidation. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1988, 90, 785-789.	0.2	1
672	Senile plaques and neurofibrillary tangles: The concurrent lesions of alzheimer's disease. Neurobiology of Aging, 1995, 16, 343-344.	3.2	1
673	The Fallacy of Amyloid and Cognition in Alzheimer???s Disease. Drugs and Aging, 2006, 23, 179.	3.0	1
674	Sequestration of p27 within the cytoplasm of cardiac myocytes in chronic ischemic heart disease: pathogenic implications for ischemic cardiomyopathy. Age, 2006, 28, 85-91.	2.9	1
675	Neurodegenerative Diseases: Mechanisms and Therapies. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-2.	2.3	1
676	Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid. Free Radical Research, 2010, 44, 734-741.	3.3	1
677	Mark A. Smith: Scholar and Innovator. European Journal of Histochemistry, 2011, 55, 2.	1.6	1
678	The Contribution of the Amyloid Hypothesis to the Understanding of Alzheimer's Disease: A Critical Overview. International Journal of Alzheimer's Disease, 2012, 2012, 1-2.	2.5	1
679	Inge Grundke-Iqbal: A Legacy of Tau in the Etiology of Alzheimer Disease (1937â€“2012). Journal of Alzheimer's Disease, 2012, 33, 1-2.	2.7	1
680	Are Alzheimer's Disease and Aging Evolutionary?. Journal of Alzheimer's Disease, 2013, 35, 637-637.	2.7	1
681	Pathogenesis of Alzheimerâ€™s Disease. , 2014, , 2327-2337.		1
682	Simultaneous Onset of Alzheimerâ€™s Disease in a Husband and Wife in Their Mid-Fifties: What Do We Really Know About Environmental Factors?. The Open Neurology Journal, 2015, 9, 1-3.	0.4	1
683	RaÃºl Mena: 1953â€“2014. Journal of Alzheimer's Disease, 2015, 45, 325-327.	2.7	1
684	Autophagy in Alzheimerâ€™s disease: A Cleaning Service Out-of-order?. Current Topics in Neurotoxicity, 2015, , 123-142.	0.0	1

#	Article	IF	Citations
685	Scientific Information Security in Information Science and Academic Publishing. Artificial Organs, 2016, 40, 425-430.	2.0	1
686	Birth of JAD: 20 Years Later. Journal of Alzheimer's Disease, 2018, 62, 901-901.	2.7	1
687	Decreased salivary lactoferrin levels are specific to Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042621.	0.7	1
688	Alzheimerâ€™s and Consciousness: How Much Subjectivity Is Objective?. Neuroscience Insights, 2021, 16, 263310552110338.	1.6	1
689	Oxidative Stress and Balance in Neurodegenerative Diseases. , 2011, , 10-12.		1
690	Neuronal Oxidative Stress is a Common Feature of Alzheimerâ€™s and Parkinsonâ€™s Diseases. Advances in Behavioral Biology, 1998, , 77-80.	0.0	1
691	Prion and Alzheimer Diseases: The Road to Pathogenesis is Paved with Copper. , 2002, , 96-101.		1
692	Unraveling the Role of Mitochondria in Alzheimerâ€™s Disease. , 2020, , 407-430.		1
693	Metal-Catalyzed Redox Activity in Neurodegenerative Disease. , 2003, , 1-14.		1
694	Antioxidant Therapies in the Prevention and Treatment of Alzheimer Disease. Oxidative Stress and Disease, 2005, , 131-145.	0.0	1
695	The Teflon hypothesis. Brain Communications, 2023, 5, .	3.4	1
696	Carbonyl-Related Modification of Neurofilaments in Aizheimer Disease. Journal of Neuropathology and Experimental Neurology, 1995, 54, 434.	1.8	0
697	Journal of Alzheimer's Disease Established as a Leading Journal. Journal of Alzheimer's Disease, 2001, 3, 521-523.	2.7	0
698	Phosphorylation, Microtubule Binding and Aggregation of Tau Protein in Alzheimer's Disease. , 0, , 601-607.		0
699	Oxidative Stress in Aging and Neurodegenerative Diseases: From Biology to Therapy, Perugia, Italy, May 2003. Journal of Alzheimer's Disease, 2004, 6, 115-115.	2.7	0
700	Metal Ions and Neurodegenerative Diseases Paolo Zatta, Editor. World Scientific Publishing Co. Pte. Ltd, Singapore, 2004, pp 400. Aging Cell, 2004, 3, 85-85.	6.8	0
701	Role of Amyloid-Î² in Alzheimer's Disease. International Journal of Experimental Pathology, 2005, 86, 131-131.	1.3	0
702	Introduction: Imaging in Alzheimer's disease. Microscopy Research and Technique, 2005, 67, 113-113.	2.3	0

#	Article	IF	Citations
703	The End of a Chilean Institute. Science, 2005, 308, 792b-793b.	20.9	0
704	Commentary on â€œPerspective on a pathogenesis and treatment of Alzheimer's disease.â€•Therapeutic strategies for Alzheimer's disease: The need for a new era of innovation. Alzheimer's and Dementia, 2006, 2, ALZJJALZ200607002.	0.7	0
705	Foreword: Apoptotic Mechanisms in Neurodegenerative Diseases. Current Alzheimer Research, 2006, 3, 267-267.	1.5	0
706	Nanoparticles for the Treatment of<scp>A</scp>lzheimer's Disease: Theoretical Rationale, Present Status and Future Perspectives. , 2003, , .		0
707	Sir Martin Roth â€“ A Debt of Gratitude. Journal of Alzheimer's Disease, 2007, 11, 1-1.	2.7	0
708	Mitochondrial autophagocytosis in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 434.	1.8	0
709	Nonestrogen-Based Hormonal Therapies for Alzheimerâ€˜s Disease. Future Neurology, 2008, 3, 399-407.	0.5	0
710	Gonadotropin effects. , 2009, , 251-274.		0
711	Is Alzheimers Disease a Myth? When is Disease a Disease?. Current Alzheimer Research, 2009, 6, 82-82.	1.5	0
712	Food Antioxidants and Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2009, , .	0.0	0
713	2009 Award Recipients-Peter C. Burger, MD, Pierluigi Gambetti, MD, and Nicholas K. Gonatas, MD. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1244-1246.	1.8	0
714	Chapter 19. Targeting Oxidative Mechanisms in Alzheimer Disease. RSC Drug Discovery Series, 2010, , 97-107.	0.0	0
715	Alzheimerâ€™s disease therapy: a moving target. Therapy: Open Access in Clinical Medicine, 2011, 8, 457-458.	0.2	0
716	Mark A. Smith, PhD: Renegade Scientist and Visionary. Journal of Neuropathology and Experimental Neurology, 2011, 70, 495-497.	1.8	0
717	Mark A. Smith. Alzheimer Disease and Associated Disorders, 2011, 25, 369-370.	1.3	0
718	Neurodegenerative Processes In Alzheimerâ€˜s Disease: An Overview of Pathogenesis With Strategic Biomarker Potential. Future Neurology, 2011, 6, 173-185.	0.5	0
719	Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest. Current Alzheimer Research, 2012, 9, 1168-1173.	1.5	0
720	Editorial [Special Issue in Honor of the 70th Birthday of Dr. Atta-ur-Rahman, FRS]. Mini-Reviews in Medicinal Chemistry, 2012, 12, i-i.	2.6	0

#	Article	IF	Citations
721	Mark Smith: Pioneer of Alzheimer Disease Research. Neurotoxicity Research, 2012, 22, 181-181.	2.7	0
722	Journal of Huntington's Disease â€" The Family Gets Bigger. Journal of Alzheimer's Disease, 2012, 30, 735-735.	2.7	0
723	Nutrients and Food Constituents in Cognitive Decline and Neurodegenerative Disease. , 2013, , 373-390.		0
724	Larry Sparks: Innovator and Iconoclast. Journal of Alzheimer's Disease, 2013, 37, 1-1.	2.7	0
725	Looking At Alzheimerâ€˜s Disease From A Different Angle. Future Neurology, 2014, 9, 19-22.	0.5	0
726	P3-029: Oxidative damage is correlated with mitochondrial autophagy. Alzheimer's and Dementia, 2015, 11, P630-P630.	0.7	0
727	P2-152: Molecular mapping of Alzheimer's disease: Imaging mass spectrometry. Alzheimer's and Dementia, 2015, 11, P545-P545.	0.7	0
728	Two Hundred Treasured Issues!. Journal of Alzheimer's Disease, 2015, 44, 725-725.	2.7	0
729	Morphometric analysis of cryofixed muscular tissue for intraoperative consultation. Microscopy Research and Technique, 2016, 79, 155-161.	2.3	0
730	Nutritional supplements and dementia. Clinical Nutrition, 2017, 36, 613-614.	5.1	0
731	Metals and Mitochondria in Neurodegeneration. , 2017, , 283-311.		0
732	Preface: Alzheimerâ€™s Disease: New Beginnings. Journal of Alzheimer's Disease, 2018, 64, S1-S1.	2.7	0
733	P4â€513: ACTIVATION OF FERROPTOSIS, AN IRONâ€DEPENDENT FORM OF NONâ€APOPTOTIC DEATH IN NEURONS. Alzheimer's and Dementia, 2019, 15, P1510.	0.7	0
734	MSDC-0160 and MSDC-0602 Binding with Human Mitochondrial Pyruvate Carrier (MPC) 1 and 2 Heterodimer. , 2021, , 427-455.		0
735	American Dementia: Brain Health in an Unhealthy Society by Daniel R. George and Peter J. Whitehouse, Johns Hopkins Press, 2021, 390 pp.. Journal of Alzheimer's Disease, 2021, 83, 935-935.	2.7	0
736	Alzheimer's and Parkinson's Disease Novel Therapeutic Target. , 2021, , 411-426.		0
737	Role of Heme Catabolism in Neurodegenerative Diseases. , 2002, , 135-143.		0
738	Neuronal Survival and Death in Alzheimer Disease. Advances in Behavioral Biology, 2002, , 49-57.	0.0	0

#	Article	IF	Citations
739	Metal Homeostasis and Its Relation to Oxidative Stress in Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2003, , .	0.0	0
740	La funciÃ³n del estrÃ©s oxidativo en la patogÃ©nesis de la enfermedad de Alzheimer. Revista Chilena De Neuro-Psiquiatria, 0, 41, .	0.2	0
741	Nutritional Antioxidants, Vitamins, Cognition, and Neurodegenerative Disease. , 2004, , 813-823.		0
742	Ciprofloxacin Does Not Exert Nephrotoxicity in Rats. American Journal of Infectious Diseases, 2005, 1, 145-148.	0.2	0
743	Amyloid- _ and _ in Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2005, , 121-129.	0.0	0
744	Temporal Primacy of Oxidative Stress in the Pathological Cascade of Alzheimer Disease. Oxidative Stress and Disease, 2005, , 365-372.	0.0	0
745	Oxidative Adaptation in Aging and Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2005, , 117-125.	0.0	0
746	The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics. , 2007, , 194-211.		0
747	Mitochondrial Autophagocytosis in Alzheimer Disease. FASEB Journal, 2007, 21, A73.	0.5	0
748	Lipoic Acid and Nâ€Acetyl Cysteine Protect Against Mitochondrialâ€Related Oxidative Stress in Fibroblasts from Alzheimer Disease Patients. FASEB Journal, 2007, 21, .	0.5	0
749	Lipoic acid and N-acetyl cysteine protect against mitochondrial-related oxidative stress in fibroblasts from Alzheimer disease patients. Journal of Neuropathology and Experimental Neurology, 2007, 66, 434.	1.8	0
750	Protein Misfolding in Alzheimer's Disease. Enzyme Inhibitors Series, 2007, , .	0.0	0
751	The primary pathogenetic role of vascular hypoperfusion, mitochondria failure and oxidative stress in aging and Alzheimer disease. FASEB Journal, 2008, 22, 167.3.	0.5	0
752	Antibodyâ€Antigen Dissociation: A Novel Diagnostic Tool in Alzheimer Disease. FASEB Journal, 2008, 22, 167.10.	0.5	0
753	Neurodegenerative Phenotypes Induced by MYCâ€Driven Neuronal Cell Cycle Reâ€entry: Relevance to Alzheimer Disease. FASEB Journal, 2008, 22, 167.6.	0.5	0
754	Cellular Respiration and Tumor Suppressor Genes. , 2009, , 131-144.		0
755	Oxidative Stress Associated Signal Transduction Cascades in Alzheimer Disease. Contemporary Clinical Neuroscience, 2009, , 121-136.	0.0	0
756	Alzheimer Disease: Oxidative Stress and Compensatory Responses. Contemporary Clinical Neuroscience, 2009, , 109-120.	0.0	0

#	Article	IF	Citations
757	Oxidative Stress and Alzheimer Disease: Mechanisms and Therapeutic Opportunities. Advances in Neurobiology, 2011, , 607-631.	0.0	0
758	Association of Mitochondrial Signaling in Alzheimerâ€™s Disease and Hypoxia. , 2011, , 50-61.		0
759	Pathological phenotype in familial neurodegenerative disease: implications for families and therapeutic constructs. Therapy: Open Access in Clinical Medicine, 2011, 8, 475-479.	0.2	0
760	Thinking Outside the Box in Alzheimer Disease Treatment. , 0, , .		0
761	A Pleotrophic Age for Alzheimer and Parkinson disease. , 2012, 02, .		0
762	Therapeutic Opportunities in Alzheimer Disease: Current Concepts. , 2012, , 767-788.		0
763	R-_-Lipoic Acid as a Potent Agent of Mitochondrial Protectionin Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2012, , 455-467.	0.0	0
764	Glial Cell Extracellular Matrix in Alzheimer's Disease. , 1995, , 158-170.		0
765	Oxidative Damage is Correlated with Mitochondrial Autophagy. FASEB Journal, 2015, 29, 613.1.	0.5	0
766	INVITED ARTICLE FROM THE 2020 TEXAS ACADEMY OF SCIENCE TEXAS DISTINGUISHED SCIENTIST. Texas Journal of Science, 2020, 72, .	0.2	0
767	Role of Oxidative Insult and Neuronal Survival in Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2008, , 133-148.		0
768	Cell Cycle Activation and the Amyloid-Î² Protein in Alzheimerâ€™s Disease. , 2006, , 299-308.		0
769	Neurogenesis in Alzheimerâ€™s Disease. , 2006, , 359-370.		0
770	Editorial: Oxidative Stress Revisitedâ€"Major Role in Vascular Diseases, Volume II. Frontiers in Physiology, 2021, 12, 826129.	2.8	0
771	Functional study in the young rTg4510 mouse model of tauopathy. Alzheimer's and Dementia, 2021, 17, e058539.	0.7	0
772	Pathogenesis of Alzheimerâ€™s Disease. , 2021, , 1-20.		0
773	The Changing landscape of Alzheimerâ€™s disease: From Insoluble to Soluble and from Pathogen to Protector. , 2006, , 367-369.		0
774	MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?. American Journal of Neuroradiology, 0, , .	2.7	0

#	Article	IF	Citations
775	Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on Î±-Synuclein and Tau Aggregation. ACS Chemical Neuroscience, 0, , .	3.7	0
776	Fabrication and Characterization of Quad-Component Bioinspired Hydrogels to Model Elevated Fibrin Levels in Central Nervous Tissue Scaffolds. Gels, 2024, 10, 203.	4.7	0
777	Label-Free In Situ Chemical Characterization of Amyloid Plaques in Human Brain Tissues. ACS Chemical Neuroscience, 2024, 15, 1469-1483.	3.7	0
778	Central role of brain regulatory T cells in the inflammatory cascade in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121, .	7.6	0
779	Sensory Dysfunction, Microbial Infections, and Host Responses in Alzheimer's Disease. Journal of Infectious Diseases, 2024, 230, S150-S164.	3.9	0